NATIONAL HEALTH LABORATORY SERVICE

National Cancer Registry



health
Department:
Health
REPUBLIC OF SOUTH AFRICA

EKURHULENI POPULATION-BASED CANCER REGISTRY 2017 ANNUAL REPORT

Johannesburg, South Africa, April 2019



Copyright © 2019

Citation:

National Cancer Registry, South Africa. Ekurhuleni Population Based Cancer Registry Annual 2017 Report. www.ncr.ac.za.

Sponsors for publication:

Compiled by:

Dr. Elvira Singh (Head of Department)

Ms. Lactatia Motsuku (Epidemiologist)

Mrs. Lerato Khoali (Surveillance Manager)

Dr. Mazvita Sengayi-Muchengeti (Senior Epidemiologist)

Mr. Wenlong Chen (Medical Scientist)

Ms Natasha Abrahams (Epidemiologist)

Ekurhuleni Cancer Registry National Cancer Registry, National Health Laboratory Service 1 Modderfontein Road, Sandringham Johannesburg South Africa 2131 Tel: +27 11 386 0548 Fax to email: +27 11 386 6516 Website: www.ncr.ac.za

TABLE OF CONTENTS

ACKNOWLEDGEMENTS	V
LIST OF TABLES	vi
LIST OF FIGURES	vi
ACRONYMS AND ABBREVIATIONS	vii
EXECUTIVE SUMMARY	viii
INTRODUCTION	1
BACKGROUND AND HISTORY	2
METHODS	4
Data Sources	5
Data Collection and Processes	8
Confidentiality	10
Statistical Methods	11
RESULTS	12
Overall Cancer Incidence	12
Results of Selected Cancers	20
Childhood cancers incidence	21
Quality	23
DISCUSSION	25
REFERENCES	27
APPENDICES	28
Apendix 1: List of Data Sources	
Apendix 2: South African Cancer Notification Form	29
Appendix 3: Tables of Incidence by site, sex, age group and population group	
Ekurhuleni 2017	30

ACKNOWLEDGEMENTS

This work has been possible through a full grant provided by the South African Medical Research Council.

The National Cancer Registry (NCR) would also like to thank all individuals, organisations and relevant stakeholders that played a critical role in the operations of Ekurhuleni Population-Based Cancer Registry.

African Cancer Registry Network	Lancet Laboratories
(AFCRN)	National Health Laboratory Services
Ampath Laboratories	National Institute for Communicable
Arebaoke Hospice	Diseases
Benoni Oncology Centre	Pathcare Laboratories
Chris Hani Baragwanath Academic	Pholosong Regional Hospital
Hospital	South African Oncology Consortium
Charlotte Maxeke Academic Hospital	(SAOC)
Department of Health, South Africa	South African Paediatric Oncology Network
Drs Gritzman & Thatcher Inc Laboratories	St Francis Hospice
Eastrand Benoni Hospice	Stepping Stone Hospice
Edenvale Regional Hospital	Steve Biko Academic Hospital
Far East Regional Hospital	Tambo Memorial Regional Hospital
Gauteng Oncology Alberton Private Hospital	Tembisa Regional Hospital
Gauteng Oncology Prostate-Clinic	Thelle Mogoerane Regional Hospital
Gauteng Oncology Linmed Private Hospital	Union for International Cancer Control (UICC)
International Agency for Research on	Vermaak Laboratories
Cancer (IARC)	World Health Organization (WHO)
International Association of Cancer Registries (IACR)	South African Medical Research Council (SAMRC)

LIST OF TABLES

Table 1: Summary statistics for all cancers in Men, Ekurhuleni (2017)	.14
Table 2: Summary statistics for all cancers in Females, Ekurhuleni (2017)	.15
Table 3: Childhood cancers	.21
Table 4: Percentage of cases Morphologically Verified, diagnosed clinically or diagnosed b	by
Death Certificate Only	.23

LIST OF FIGURES

Figure 1: Ekurhuleni Metropolitan Municipality map	4
Figure 2: Population of Ekurhuleni Metropolitan Municipality in 2016	4
Figure 3: Ekurhuleni Population-based cancer registry data sources map	7
Figure 4: Ekurhuleni Population Based Cancer Registry data flow diagram	8
Figure 5: Total cancer cases by gender and race	.12
Figure 6: Frequency of top 10 most common cancers in males	.17
Figure 7: Age Standardised Incidence Rates for Top 10 Cancers in Males	.17
Figure 8: Frequency of top 10 common cancers in females	.18
Figure 9: Age standardised incidence rates for the top 10 cancers in females	.18
Figure 10: ASR of common cancers in men by population group	.19
Figure 11: ASR of common cancers in women by population group	.19
Figure 12: Age Specific Incidence Rates in Males	.22
Figure 13: Age Specific Incidence Rates for Females	.22

ACRONYMS AND ABBREVIATIONS

AFCRN	: African Cancer Registry Network
DoH	: Department of Health, South Africa
DoHA	: Department of Home Affairs, South Africa
EPBCR	: Ekurhuleni Population-Based Cancer Registry
IACR	: International Association of Cancer Registries
IARC	: International Agency for Research on Cancer
ICCC	: International Classification of Childhood Cancer
ICDO-3	: International Classification of Diseases for Oncology Third Edition
NCR	: National Cancer Registry, South Africa
POPI Act	: Protection of Personal Information Act, South Africa
SA	: South Africa
SAMRC	: South African Medical Research Council
SAOC	: South African Oncology Consortium
STATSSA	
	: Statistics, South Africa
UICC	: Statistics, South Africa : Union for International Cancer Control
UICC WHO	
	: Union for International Cancer Control

EXECUTIVE SUMMARY

Cancer is the second leading cause of death in the world, accounting for an estimated 9.6 million deaths in 2018 according to the International Agency for Research on Cancer (IARC). The measures for cancer control and prevention are dependent on quality cancer data in order to inform policies, guidelines and implementation programmes. Cancer surveillance provides the most comprehensive estimates of cancer burden through systematic collection, storage, analysis, interpretation and reporting of cancer cases.

This is the first report from the Ekurhuleni Population Based Cancer Registry (EPBCR) on cancer incidence in an urban municipality in Gauteng, South Africa. The establishment of this registry was possible through a grant provided for 3 years by the South African Medical Research Council. Ekurhuleni has a population of 3 379 104 persons, and represents over 6% of the population of South Africa with a heterogeneous composition of population groups. The EPBCR was established in 2016 and a phased approach to data collection was adopted due to the large number of potential data sources. First, all public hospitals and private medical /radiation oncology facilities were included, followed by independent private practitioners. The EPBCR employs cancer registration guidelines developed by the International Association of Cancer Registries (IACR), the International Agency for Research on Cancer (IARC) and the African Cancer Registry Network (AFCRN).

A total of 3371 cancer cases were registered for 2017 with 58.0% of cases being female. The majority of cases were diagnosed in the Black population (62.7%), followed by 34% in the White population. The common cancers amongst males (ranked by age standardised incidence rates) were prostate, colorectal, lung, Non-Hodgkins lymphoma and oesophageal cancers. The top five cancers amongst women were breast, cervical, colorectal, uterine and lung cancers. The morphological verification rate for the EPBCR was over 90%. Only 110 cancers were

reported with age unknown. There were 88 cases of cancer (2.6%) reported where the primary site was unspecified or uncertain.

Future strategic priorities for the EPBCR will involve optimisation of data collection from private sources, male patients and children. Funding for the EPBCR will need to be sourced from core business funds rather than grant funding to sustain the registry, as the activities are mandated by Regulation 380 of the National Health Act. Formalised quality assurance activities will be conducted in the new year, including an assessment of completeness of the registry data collection in collaboration with the AFCRN

•

INTRODUCTION

Cancer is the second leading cause of mortality in the world, accounting for an estimated 9.6 million deaths in 2018 according to the International Agency for Research on Cancer (IARC) (1). The cancer burden is rising in low and middle-income countries adding to the burden of diseases in the African region (2). The rise is attributed to the ageing population, changes in lifestyle and altered communicable diseases epidemiology (3). There is an urgent need to implement multi-disciplinary and collaborative efforts to prevent and control cancer morbidity and mortality.

The measures for cancer control and prevention are dependent on quality cancer data in order to inform policies, guidelines and implementation programmes (4). Cancer surveillance provides the most comprehensive estimates of cancer burden through systematic collection, storage, analysis, interpretation and reporting of cancer cases(5). In Africa, comprehensive quality data on cancer is very limited (6). Only 2% of the African population contributes to the GLOBOCAN report and the data is insufficient to describe the true burden of cancer for the continent (6).

In South Africa, cancer surveillance is the responsibility of the National Cancer Registry (7,8). Its functions include the enumeration of cancer cases, the calculation of cancer incidence for the country and the description of cancer risk factors, through the current operation of a pathology-based cancer registry and the new population-based cancer registry (7). Since 1986 the NCR has conducted pathology-based cancer registration which underestimated the true burden of cancer in the country; hence the establishment of the Ekurhuleni Population-Based Cancer Registry (EPBCR) (9).

The purpose of this document is to outline the National Cancer Registry's background and its approach for collecting, storing, cleaning, analysing, reporting, and presenting population

based cancer data, and to report the 2017 Ekurhuleni Population-Based Cancer Registry incidence.

BACKGROUND AND HISTORY

In 2011, the South African Department of Health enacted Regulation No 380 of the National Health Act (Act 61 of 2003), which formally established the National Cancer Registry (NCR) as its delegated agency for the collection of cancer surveillance information (8). This regulation made cancer a reportable disease with every health-care worker obligated to report confirmed cancers to the NCR (8,10). Cancer surveillance systems in South Africa were restricted to pathology-based national surveillance programmes and smaller, independent clinical-based registries that did not formally report to the NCR(9). These registries did not have the resources to collect robust cancer incidence data, which can be used to estimate national cancer incidence (9). In view of the size of the South African population, an estimated minimum of four population-based cancer registries will be needed to confidently extrapolate national cancer incidence (9).

The Ekurhuleni Metropolitan District is an ethnically and socioeconomically diverse urban community selected as one of the sites for the four population-based cancer registries (9). The name Ekurhuleni means 'place of peace' in Tsonga, and the municipality is one of three metropolitan municipalities within the Gauteng Province (11). Ekurhuleni is highly urbanized, with 99,4% of the population living in urban settlements ranging from informal settlements to elite urban residential suburbs (11). As of March 2017, the Ekurhuleni Population-Based Cancer Registry has 9 surveillance officers that actively collect cancer data of Ekurhuleni residents from regional and tertiary public hospitals, private healthcare facilities and hospices. Data collection from *all* healthcare facilities and reporting sources began in January 2017. This


is the first cancer incidence report for the Ekurhuleni District accounting for all cancers diagnosed in 2017, the first year of complete data collection in the EPBCR.

The Ekurhuleni Population-Based Cancer Registry is managed by the South African National Cancer Registry, National Health Laboratory Service.

Population Covered

i. Geography

The City of Ekurhuleni Metropolitan Municipality is a metropolitan municipality that forms the local government of the East Rand region of Gauteng, South Africa (12). Ekurhuleni Metropolitan Municipality occupies 1 975km² in the east of Gauteng province (11). Ekurhuleni consists of nine, relatively small, towns: Alberton, Benoni, Boksburg, Brakpan, Edenvale, Germiston and Kempton Park, Nigel and Springs (11). Of these, Kempton Park, Benoni, and Springs are the largest (11). It also incorporates four previously disadvantaged communities namely Tembisa, the Katorus complex, the Kwatsaduza complex, and the Daveyton Etwatwa area (11).



ii. Population Size and Composition

Ekurhuleni has a population of 3,379,104 persons, a population density of 1609 persons/km² and a population growth rate of 2.4% (13). Ekurhuleni represents over 6% of the population of South Africa (13). Figure 2 below shows the population pyramid of Ekurhuleni according to the 2016 Community survey (13).




Figure 2: Population of Ekurhuleni Metropolitan Municipality in 2016

METHODS

The Ekurhuleni Population-Based Cancer Registry employs cancer registration guidelines and strategies developed by the International Association of Cancer Registries (IACR), the International Agency for Research on Cancer (IARC) and the African Cancer Registry Network (AFCRN). In short, the EPBCR employs both passive and active surveillance, collecting data on all cancer patients residing in Ekurhuleni metropolitan municipality diagnosed by clinical, radiological, pathology or any other means of investigations.

Data Sources

i. Government and Private Hospitals/Healthcare Facilities

Ekurhuleni population-based cancer registry has multiple data sources. The data sources extend beyond the borders of the Ekurhuleni metropolitan municipality due to the nature of the South African healthcare referral system. The municipalities do not often have all levels of care (level 1: Primary health care clinic, Community health care center, District hospital, level 2: Regional hospital, level 3: Provincial tertiary hospital, and level 4: Central hospital and Specialised hospital) within its borders (14). Therefore, patients may be referred out of the municipality to access further diagnosis and management (14). Secondly, South African patients are a highly mobile population and have the freedom to choose the healthcare facility they prefer, which is often not necessarily within the borders of the district they reside in.

In addition to the public healthcare facilities, South Africa also has a large and well-resourced private healthcare industry. Sixteen percent of the South African population has medical health insurance and is thus able to access healthcare in private healthcare facilities. Therefore, in order to obtain complete reporting from the Ekurhuleni District's population, the EPBCR also collects data from private hospitals, and clinicians in independent private practice (See Appendix 1 for a comprehensive list).

ii. Laboratories, Oncology Networks and Associations

South Africa has an expansive network of both public and private laboratories. An estimated 80% of the SA's population is serviced by NHLS, which has 268 (as of March 2019) laboratories around nine provinces of SA (15). The other estimated 20% of the population is covered by private laboratories which include but not limited to: Ampath, Pathcare and Lancet

laboratories. Both public and private laboratories send electronic reports of patients diagnosed with cancer through the NCR national pathology surveillance programme. The surveillance officers use all the pathology reports received from laboratories together with other data tools (medical files, hospital register, pharmacy list etc.) to check, identify, trace and register patients from Ekurhuleni metropolitan municipality into the EPBCR.

In addition, The South African Pediatric Oncology Group and the South African Oncology Consortium (SAOC) report their relevant data to the NCR. The surveillance officers use these data sources to consolidate missing information for patiens already registered in the EPBCR database, or to trace and notify the patient in conjunction with other data tools from different data sources.

Finally, surveillance officers use hospital registers, patient files and mortuary records to identify new patients not already recorded in an existing database available to the NCR.

iii. The Hospice

Other than the hospitals, laboratories, cancer networks and associations, the surveillance officers visit hospices at regular intervals in order to consolidate information missing for patients already registered from other data sources such as hospitals, as well as to report any new patients identified.

iv. Vital Statistics (Death Registration)

The Department of Home Affairs (DoHA) is the custodian of vital statistics for SA. The Statistics South Africa (STATSSA) also has cleaned vital statistics data for South Africans that can be used to consolidate vital status (i.e. dead/alive) in the EPBCR. However, STATSSA is unable to legally share patient level data with other official organisations. To compensate for the challenge, the surveillance officers visit the mortuaries within health facilities in order to trace and report cases of cancer for patients who may have been missed while alive.

Figure 3 below illustrates the data sources for Ekurhuleni Population-based cancer registration as of 31 December 2018.




Figure 3: Ekurhuleni Population-based cancer registry data sources map

Data Collection and Processes

Figure 4 below illustrates the data flow for the EPBCR




Figure 4: Ekurhuleni Population Based Cancer Registry data flow diagram

The EPBCR uses both active and passive methods of case finding.

Active case finding:

• The surveillance officers visit healthcare facilities to review electronic and/or physical records of patients such as patient files, admission registers, pathology reports, radiology reports, death registers, outpatient registers, pharmacy registers and clinician's statistical records in order to notify confirmed cancer cases on the cancer notification forms.

Passive case finding:

• As mentioned above, both the South African Paediatric Oncology Research Group and the South African Oncology Consortium (SAOC) passively provide data to the NCR for the Ekurhuleni district.

Inclusion criteria for both active and passive case finding methods:

- All confirmed cancer cases, in persons who are resident in the Ekurhuleni Metropolitan Municipality, diagnosed since 1st January 2017 must be reported to the registry.
- Cancer cases include:
 - Cases considered as malignant in the morphology section of the International Classification of Diseases for Oncology (ICD-O); behavior code-3 are reported to the registry.
 - Cancers in metastatic sites (for example, lymph nodes) are registered with the primary tumor site topography. If this is not known, it is registered as an unknown primary site

The surveillance officers extract data/variables required (See Appendix 2: South African Cancer Notification Form) from data sources such as medical records, and code the cancer diagnosis according to the International Classification of Diseases for Oncology 3rd edition (ICDO-3) for topography and morphology. A pathology report, where available, is filed with the corresponding notification form. Reports are filed according to the date and facility of diagnosis.

The files are then sent to data capturers for data entry on the RedCap system. The NCR uses RedCap instead of the IARC recommended CanReg system because CanReg did not meet the current data processing requirements, such as large storage capacity, simultaneous multiple users and virtual network use.

The captured files are sent to the surveillance manager for quality assurance and quality control. The Surveillance manager uses both the physical notification forms and electronic records on Redcap for each individual cancer case to check for duplicates, completeness, and consistency. The files are stored in a locked cabinet for 20 years as per the South Africa Protection of Personal Information Act (POPI Act) before they are permanently destroyed (16).

The completed, quality assured dataset is extracted per year (1st January to 31st December for each year) for cleaning and analysis on Stata.

The analyzed data is then used for annual incidence reports, teaching/training, and research purposes.

Confidentiality

The NCR adheres to the NHLS, the IARC/IACR guidelines and the POPI Act to ensure the preservation of confidentiality during EPBCR surveillance process (16). Request to use EPBCR data by entities/individuals is sought in writing to the NCR. The statistics of cancer data are released in an aggregated format through the annual reports published on the NCR website.

Statistical Methods

The results are presented as:

- the number of new cancer cases,
- the percentage of all new cancer cases,
- adjusted cancer cases per 100,000 population,
- Age-Standardised Incidence Rate (ASR) per 100,000 and
- Lifetime risk for 2017 (1St January 2017-31st December 2017)

The results are further stratified by:

- sex (Male and Female),
- population group (Black, White, Asian & Coloured) and
- age groups (5 year interval e.g. 0-5 years, 5-10, 10-15 etc.).

For Age standardization, the Segi-World Standard Population (WSP) is used as per international cancer registration norms. STATSSA mid-year population data for Ekurhuleni metropolitan municipality is used as a denominator.

The Calculation methods are as follows:

Crude	=	Number of new cases X 100,000 Mid-year population
WSP weighting	=	WSP (for each age group)X 100,000Total WSP for all age groups
ASR	=	Crude X WSP weighting

RESULTS

Overall Cancer Incidence

A total of 3371 cancers were registered by the EPBCR for 2017 of which 1414 (42%) occurred in males and 1957 (58%) occurred in females. Benign, in-situ cancers and cancers of unknown behaviour were excluded from the data collection and analysis.

Figure 1 below shows the total number of cancer cases (frequency and percentage) diagnosed in 2017 by gender and race. 62.7% of cases were diagnosed in the Black population and 34% in the White population. The Coloured and Asian populations contributed \approx 1% each by gender.

Frequency of cancer cases by gender and race, 2017 (n=3371)




Figure 5: Total cancer cases by gender and race

Table 1 and 2 illustrate a detailed tabulation of cases registered in 2017 for males and females. The tables show the total number of cases registered, crude rates per 100000 population, ageadjusted incidence rates per 100000 population, and lifetime risk for each cancer. Appendix tables further elaborate on these data by demonstrating age standardised and age specific incidence rates by population group and gender.

MALES									
SITE	N*	(%)	CRUDE RATE	ASR	CUM 0-74	ICD 10			
All sites	1414	100.0	86.1	88.1	9.9				
All sites but C44	1307	92.4	79.6	81.4	9.2				
Prostate	471	33.3	28.7	30.6	3.9	C61			
Colorectal	103	7.3	6.3	6.4	0.7	C18			
Lung	70	5.0	4.3	4.4	0.5	C34			
Non Hodgkin lymphoma	59	4.2	3.6	3.2	0.3	C84			
Kaposi Sarcoma	56	4.0	3.4	2.8	0.2	C46			
BCC	54	3.8	3.3	3.4	0.4	C44			
Primary site unknown	51	3.6	3.1	3.2	0.4	C80			
Oesophagus	48	3.4	2.9	3.0	0.3	C15			
Leukaemia	36	2.6	2.2	2.4	0.2	C92			
Melanoma	35	2.5	2.1	2.2	0.3	C43			
Stomach	32	2.3	1.9	2.0	0.3	C16			
SCC of skin	28	2.0	1.7	1.7	0.2	C44			
Pancreas	25	1.8	1.6	1.6	0.2	C25			
Skin other	25	1.8	1.5	1.6	0.2	C44			
Hodgkin lymphoma	23	1.6	1.4	1.4	0.1	C81			
Brain. CNS	21	1.5	1.3	1.3	0.2	C71			
Other specified	20	1.4	1.2	1.2	0.1	C63			
Bladder	19	1.3	1.2	1.2	0.1	C67			
Naso-Oropharynx	18	1.3	1.1	1.1	0.1	C11			
Liver & Bile duct	18	1.3	1.1	1.1	0.1	C22			
Larynx	18	1.3	1.1	1.2	0.2	C32			
Kidney	18	1.3	1.1	1.2	0.1	C64			
Myeloma	18	1.3	1.1	1.1	0.2	C90			
Mouth	17	1.2	1.0	1.1	0.1	C06			
Tongue	15	1.1	0.9	1.0	0.1	C02			
Anus	15	1.1	0.9	0.9	0.1	C21			
Ill defined	13	0.9	0.8	0.8	0.1	C76			
Connective tissue	11	0.8	0.7	0.7	0.1	C49			
Eye	11	0.8	0.7	0.7	0.0	C69			
Salivary gland	9	0.6	0.5	0.6	0.1	C07			
Breast	9	0.6	0.5	0.5	0.1	C50			
Penis	9	0.6	0.5	0.5	0.1	C60			
Bone	8	0.6	0.5	0.5	0.0	C41			
Testis	7	0.5	0.4	0.4	0.0	C62			
Haematology other	7	0.5	0.4	0.4	0.0	C96			
Mesothelioma	6	0.4	0.4	0.4	0.0	C45			
Thyroid	3	0.2	0.2	0.2	0.0	C73			
Endocrine	3	0.2	0.2	0.2	0.0	C74			
Lip	2	0.1	0.1	0.1	0.0	C00			
Gum	1	0.1	0.1	0.1	0.0	C03			
Small intestine	1	0.1	0.1	0.1	0.0	C17			
Burkitt lymphoma	1	0.1	0.1	0.0	0.0	C83			

Table 1: Summary statistics for all cancers in Men, Ekurhuleni (2017)

N* includes cases with unknown age

FEMALES									
SITE	N*	(%)	CRUDE RATE	ASR	CUM 0-74	ICD 10			
All sites	1957	100	112.7	117.0	11.3	ALL			
All sites but C44	1885	96.32	108.5	112.1	10.9	ALL but C44			
Breast	576	29.43	33.2	33.8	3.5	C50			
Cervix	481	24.58	27.7	25.6	2.6	C53			
Colorectal	110	5.62	6.3	7.1	0.7	C18			
Uterus	81	4.14	4.7	6.0	0.6	C54			
Lung	65	3.32	3.7	4.7	0.5	C34			
Ovary	54	2.76	3.1	3.5	0.3	C56			
Non Hodgkin lymphoma	46	2.35	2.6	2.5	0.3	C84			
Vulva	41	2.1	2.4	1.9	0.2	C51			
Primary site unknown	38	1.94	2.1	2.5	0.3	C80			
Kaposi Sarcoma	33	1.69	1.9	1.6	0.1	C46			
Oesophagus	31	1.58	1.8	2.2	0.3	C15			
BCC	30	1.53	1.7	2.0	0.2	C44			
Liver & Bile duct	27	1.38	1.6	1.7	0.2	C22			
Leukaemia	23	1.18	1.3	1.6	0.1	C92			
Pancreas	23	1.18	1.3	1.5	0.2	C25			
Melanoma	22	1.12	1.3	1.4	0.2	C43			
SCC of skin	22	1.12	1.3	1.6	0.1	C44			
Myeloma	21	1.07	1.2	1.5	0.2	C90			
Skin other	20	1.02	1.2	1.3	0.1	C44			
Brain. CNS	19	0.97	1.1	1.3	0.1	C71			
Thyroid	17	0.87	1.0	0.9	0.1	C73			
, Hodgkin lymphoma	16	0.82	0.9	0.8	0.1	C81			
Connective tissue	14	0.72	0.8	0.7	0.1	C49			
Anus	13	0.66	0.7	0.7	0.0	C21			
Kidney	13	0.66	0.7	0.8	0.1	C64			
Other specified	12	0.61	0.7	0.7	0.1	C63			
Eye	11	0.56	0.6	0.6	0.1	C69			
Stomach	11	0.56	0.6	0.8	0.1	C16			
Tongue	11	0.56	0.6	0.7	0.1	C02			
Ill defined	10	0.51	0.6	0.8	0.1	C76			
Naso-Oropharynx	10	0.51	0.6	0.7	0.0	C11			
Larynx	8	0.41	0.5	0.5	0.1	C32			
Vagina	8	0.41	0.5	0.4	0.0	C52			
Bladder	7	0.36	0.4	0.5	0.1	C67			
Endocrine	7	0.36	0.4	0.5	0.0	C74			
Bone	6	0.31	0.3	0.3	0.0	C41			
Haematology other	6	0.31	0.3	0.4	0.0	C96			
Mouth	6	0.31	0.3	0.4	0.1	C06			
Salivary gland	3	0.15	0.2	0.2	0.0	C07			

Table 2: Summary statistics for all cancers in Females, Ekurhuleni (2017)

Lip	2	0.1	0.1	0.1	0.0	C00
Mesothelioma	2	0.1	0.1	0.1	0.0	C45
Small intestine	1	0.05	0.1	0.1	0.0	C17

 N^* includes cases with unknown age

Figure 6-9 below illustrate the frequency and age-standardised incidence rates of the most common cancers registered in the EPBCR in 2017 for males and females. Frequency of cancers is useful for determining the burden on a country's health care systems of screening, diagnosis and treatment of cancers. Age-standardised incidence rates are used to compare rates of cancers between geographic regions and populations. Prostate cancer was the commonest cancer amongst males (n=462; ASIR= 30.6/100 000). While the highest burden of cancer amongst females was from breast cancer (n=562; ASR=33.8/100 000), this was closely followed by cervical cancer (n=476; ASR= 25.6/100 000).

Figures 10-11 show a comparison of age-standardised incidence rates of the top 5 cancers by population group for men and women. While the Black population has the most numbers of cancers (Figure 5), it is interesting to note that the rates of the commonest cancers (ie prostate and breast) are highest amongst the White population. The small numbers of cancers collected for the Asian population make the rates of less common cancers such as Kaposi's sarcoma and cervix difficult to interpret.




Figure 6: Frequency of top 10 most common cancers in males *Only cases with known ages included




Figure 7: Age Standardised Incidence Rates for Top 10 Cancers in Males




Figure 8: Frequency of top 10 common cancers in females *Only cases with known ages included




Figure 9: Age standardised incidence rates for the top 10 cancers in females




Figure 10: ASR of common cancers in men by population group




Figure 11: ASR of common cancers in women by population group

Results of Selected Cancers

Breast Cancer

Breast cancer was the most commonly diagnosed cancer in females in the Ekurhuleni District with an ASR of 33.8/100 000 and a lifetime risk of 1:42 women. White and Asian women had the highest risk of breast cancer with ASR of 48 and 41 /100 000 respectively. 1:23 Asian women and 1:19 white women were at risk for breast cancer before age 74 years.

Breast cancer is one of the commonest female cancers in the developed world indicating the influence of lifestyle risk factors on the epidemiology. It makes sense, therefore, that rates are higher in the White and Asian populations in South Africa, as these are generally socio-economically advantaged populations.

While the rates amongst Black women are lower than in White women at 30/100 000, this rate is higher than the national rates of breast cancer reported by the national pathology-based cancer registry of 18/100 000. This supports the motivation to develop population based cancer registration for South Africa where the case definition is inclusive and where active surveillance is possible.

Cervical Cancer

Cervical cancer accounted for a quarter of all cancers diagnosed in females in Ekurhuleni in 2017 (n=481). The age-standardised incidence rate was $26/100\ 000$ and 1:38 were at risk for cervical cancer. Rates of cervical cancer were highest amongst black women at $34.6/100\ 000$; the next highest being Coloured women with a rate of $10.3/100\ 000$. The rates of cervical cancer in South Africa are linked to the HIV epidemic with highest rates in high prevalence HIV populations.

Colorectal Cancer

There were 213 colorectal cancer cases diagnosed in males and females in 2017. There were more cases diagnosed in women with a rate of 7.1/100 000 compared to 6.1/100 000 in men. Colorectal cancer was the second most common cancer diagnosed in men and the third in women. Rates were highest in White and Coloured populations.

Prostate Cancer

There were 471 cases of prostate cancer reported to the Ekurhuleni Population Based Cancer Registry in 2017 resulting in an ASR for all males of 30.6/100 000 and a lifetime risk of 1:25

men. White males had the highest risk for prostate cancer with 1:17 men at risk and an ASR of 49/100 000. Black, Asian and Coloured men had similar ASR's ranging between 26-28/100 000. While prostate cancer is generally a disease related to ageing, it is interesting to note an increase in age-specific incidence rates at age 45 years for men in the Ekurhuleni district and another increase at age 55 years. Further investigation will be required to determine the population groups associated with earlier onset of prostate cancer to inform prostate cancer guidelines and policies for screening.

Childhood cancers incidence

Table 3 below shows the top 10 cancers in children aged 0-14 years in the Ekurhuleni area. A total of 55 Cancers were registered in 2017 among children. Paediatric cancers accounted for 1.63 % of all cancers registered in 2017. There were more cancers amongst young boys than girls. Leukaemia's and lymphomas were the most common cancers amongst children.

	Number of cases							Rates per million			
	0-4 yrs	5-9 yrs	10-14 yrs	All	M/F	Relative Frequency (%)	0-4 yrs	5-9 yrs	10-14 yrs	Crude	ASR
Leukaemia	5	4	3	12	2	21.82	17.45	15.82	13.2	15.65	15.69
Lymphoma	0	2	4	6	2	10.91	0	7.91	17.6	7.82	7.66
CNS Neoplasm	2	1	2	5	0.67	9.09	6.98	3.95	8.8	6.52	6.53
Neuroblastoma	2	0	0	2	1	3.64	6.98	0	0	2.61	2.70
Retinoblastoma	5	0	0	5	4	9.09	17.45	0	0	6.52	6.75
Nephroblastoma - Wilms	2	4	1	7	0.75	12.73	6.98	15.82	4.4	9.13	9.08
Bone Tumour	2	0	1	3	2	5.45	6.98	0	4.4	3.91	3.98
Soft Tissue Sarcoma	3	0	4	7	0.75	12.73	10.47	0	17.6	9.13	9.16
Germ Cell Tumour	1	0	0	1		1.82	3.49	0	0	1.30	1.35
Other	3	3	1	7	2.5	12.73	10.47	11.86	4.4	9.13	9.16
All	25	14	16	55	1.5	100	87.23	55.35	70.39	10.12	10.24

Table 3: Childhood cancers




Figure 12: Age Specific Incidence Rates in Males




Figure 13: Age Specific Incidence Rates for Females

Figures 12-13 illustrate the age-specific incidence rates for the 5 most common cancers amongst men and women with cancer incidence rates increasing with age.

Quality

a) Basis of Diagnosis

Table 4 demonstrates the proportion of cases morphologically verified (MV) using histology, cytology or bone marrow aspirate and trephine, diagnosed by clinical means or registered from death certificate-only information (DCO).

Table 4: Percentage of cases Morphologically Verified, diagnosed clinically or diagnosed by Death Certificate Only

				Basis of Diagnosis			
Site	ICD10	No of cases	Total %	DCO %	Clinical %	MV %	
Lip	C00	4	0.12	0.0	0.0	100.0	
Tongue	C02	26	0.77	0.0	0.0	100.0	
Gum	C03	1	0.03	0.0	0.0	100.0	
Mouth	C06	23	0.68	0.0	13.0	87.0	
Salivary gland	C07	12	0.36	0.0	0.0	100.0	
Naso-Oropharynx	C11	28	0.83	0.0	7.1	92.9	
Oesophagus	C15	79	2.34	1.3	5.1	93.7	
Stomach	C16	43	1.28	0.0	7.0	93.0	
Small intestine	C17	2	0.06	0.0	50.0	50.0	
Colorectal	C18	213	6.32	0.5	5.6	93.9	
Anus	C21	28	0.83	0.0	14.3	85.7	
Liver & Bile duct	C22	45	1.33	0.0	8.9	91.1	
Pancreas	C25	48	1.42	0.0	8.3	91.7	
Larynx	C32	26	0.77	0.0	3.8	96.2	
Lung	C34	135	4.00	0.0	3.7	96.3	
Bone	C41	14	0.42	0.0	7.1	92.9	
Melanoma	C43	57	1.69	0.0	3.5	96.5	
BCC	C44	84	2.49	0.0	10.7	89.3	
SCC of skin	C44	50	1.48	0.0	12.0	88.0	
Skin other	C44	45	1.33	0.0	2.2	97.8	
Mesothelioma	C45	8	0.24	0.0	25.0	75.0	
Kaposi's Sarcoma	C46	89	2.64	0.0	16.9	83.1	
Connective tissue	C49	25	0.74	0.0	0.0	100.0	
Breast	C50	585	17.35	0.0	4.3	95.7	
Vulva	C51	41	1.22	0.0	7.3	92.7	
Vagina	C52	8	0.24	0.0	12.5	87.5	
Cervix	C53	481	14.27	0.4	8.3	91.3	
Uterus	C54	81	2.40	1.2	7.4	91.4	
Ovary	C56	54	1.60	0.0	14.8	85.2	
Penis	C60	9	0.27	0.0	11.1	88.9	
Prostate	C61	471	13.97	0.0	10.6	89.4	

Testis	C62	7	0.21	0.0	0.0	100.0
Other specified	C63	32	0.95	0.0	3.1	96.9
Kidney	C64	31	0.92	0.0	0.0	100.0
Bladder	C67	26	0.77	0.0	7.7	92.3
Еуе	C69	22	0.65	0.0	9.1	90.9
Brain, CNS	C71	40	1.19	0.0	17.5	82.5
Thyroid	C73	20	0.59	0.0	0.0	100.0
Endocrine	C74	10	0.30	0.0	0.0	100.0
Ill defined	C76	23	0.68	0.0	4.3	95.7
Primary site unknown	C80	89	2.64	0.0	7.9	92.1
Hodgkin lymphoma	C81	39	1.16	0.0	0.0	100.0
Burkitt lymphoma	C83	1	0.03	0.0	0.0	100.0
Non Hodgkin lymphoma	C84	105	3.11	0.0	9.5	90.5
Myeloma	C90	39	1.16	0.0	41.0	59.0
Leukaemia	C92	59	1.75	0.0	15.3	84.7
Haematology other	C96	13	0.39	0.0	30.8	69.2
All sites		3371	100	0.1	8.1	91.8

b) Primary site unknown (PSU)

There were 88 cases of cancer (2.6%) reported where the primary site was unspecified or uncertain from the available documentation. The rates of PSU were 3.2 and 2.5/100 000 in men and women respectively.

c) Age unknown

There were 53 cases of cancer with unknown age amongst females and 57 amongst males.

DISCUSSION

This is the first data to be published from the Ekurhuleni Population-Based Cancer Registry, which accounts for 6% of the South African population. The Ekurhuleni Registry is based in an urban municipality with an appropriate representation of the different population groups in South Africa.

We found the most common cancers registered in the EPBCR to be prostate, colorectal and lung amongst men and breast, cervix and colorectal amongst women. Leukaemia was the most common cancer diagnosed in children. Over 90% of cancers were morphologically verified and only 2.6% of cancers had an uncertain primary site. There were 110 cancer cases notified with an unknown age.

It is reassuring that, with few exceptions, the general pattern of cancers in the EPBCR reflect that recorded in the NCR's pathology based cancer registry. The leading cancers in the pathology-based registry for many years have been prostate, colorectal, lung, breast and cervix. Non-Hodgkin's lymphoma appears higher up in the ranking of cancers in the EPBCR compared to the pathology-based registry, and future data collection will determine if this is a true reflection of the cancer epidemiology in the area or an artefact of data collection methods.

Illustrations of age-specific incidence rates are useful to determine the age groups during which cancer incidence begins to increase. Comparisons with other geographic areas may alert policy makers to unusual risk factors in particular populations resulting in earlier cancerous cell growth and genesis. Our illustration of age-specific incidence rates is as expected with cancer risk higher in older age groups. The age pattern of NHL is interesting with age of onset earlier than other cancers, influenced by the HIV epidemic. This is similar to findings in other developing countries as compared to developed countries where common age of onset is 65 years and older(17).

Morphological verification in the EPBCR is high at over 90%. This may be a representation of abundant access to laboratory services in both the public and private healthcare sectors of South Africa resulting in significant numbers of biopsy confirmed cancers.

Data collection in the EPBCR has posed many challenges. It has been difficult to obtain a comprehensive list of private practitioners and practices in the Ekurhuleni area from a single source. The team has had to rely on word of mouth referrals to new data sources. As a result, new sources for notification are constantly being added to our list. In addition, to ensure

complete coverage, practitioners from many specialities other than radiation and medical oncology need to be included, as cancers can be diagnosed by any medical practitioner or specialist. Thus, the numbers of private practitioners to be covered are large.

In the coming year, the EPBCR will focus on inclusion of outstanding data sources in the Ekurhuleni area. These included dermatologists, urologists and surgeons in private, independent practice. From existing data sources, case finding for certain groups of patients such as men and children will be strengthened. A formalised QA/QC plan will be implemented in 2019 ensuring ongoing QA of notifications. A second external evaluation of the EPBCR, including an assessment of completeness of the registry data collection will be planned for the new financial year.

As the grant for the EPBCR will be ending in October 2019, sustainable funding for the EPBCR will be required. The NCR anticipates that the establishment of the National Public Health Institutes of South Africa, will provide the impetus for core, sustainable funding for the EPBCR. Once financial stability has been attained, the organogram of the EPBCR will require positions for project management and administration to be added.

The leading cancers in Ekurhuleni district reflect a mixed cancer burden consistent with the economic and racial diversity of South Africa. This comprises cancers (such as breast, prostate, colorectal and lung) of importance in high human development index (HDI) countries as well as infection-related cancers such as cervix and Kaposi's sarcoma which are prominent in low HDI countries. Cancer control policies in South Africa need to target both westernization (lifestyle, dietary and hormonal) and poverty related (infection-related) cancer risk factors.

REFERENCES

- 1. Pannitteri G, Tsoumis C, Testa U. Triterpenoids in cardiovascular medicine: Basic biology and clinical applications. Vol. 19, Current Topics in Pharmacology. 2015. p. 39–50.
- 2. Ekwueme D, Ding E, Husseini A, Tran BX, Khubchandani J, Søreide K, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. JAMA Oncol. 2016 Apr;3(4):524.
- 3. Marrero S, Adashi EY. Noncommunicable diseases. Semin Reprod Med. 2015;33(1):35–40.
- 4. World Health Organization (WHO). Cancer prevention and control in the context of an integrated approach: report by the Secretariat. 2016.
- 5. Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. Eur J Cancer [Internet]. 2009 Mar [cited 2014 Aug 20];45(5):756–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19128954
- Bray F, Møller B, Soerjomataram I, Ferlay J, Antoni S. An assessment of GLOBOCAN methods for deriving national estimates of cancer incidence. Bull World Health Organ. 2016 Mar;94(3):174–84.
- Singh E, Underwood JM, Nattey C, Babb C, Sengayi M, Kellett P. South African National Cancer Registry: Effect of withheld data from private health systems on cancer incidence estimates. South African Med J [Internet]. 2015;105(2):107. Available from: http://www.samj.org.za/index.php/samj/article/view/8858
- 8. Department of Health. Regulations relating to cancer registration. National Health Act, 2003. Gov Gaz. 2011;(34248):2–8.
- 9. Singh E, Ruff P, Babb C, Sengayi M, Beery M, Khoali L, et al. Establishment of a cancer surveillance programme: The South African experience. Vol. 16, The Lancet Oncology. NIH Public Access; 2015. p. e414–21.
- 10. Singh E, Ruff P, Babb C, Sengayi M, Beery M, Khoali L, et al. Establishment of a cancer surveillance programme: The South African experience. Lancet Oncol. 2015;16(8).
- 11. Ekurhuleni Metropolitan Municipality. ANNEXURE A Integrated Development Plan DRAFT. 2016.
- 12. INTEGRATED, (IDP) DP, OF, OF C, EKURHULENI. full-text. 2018.
- 13. Statistics South Africa. Provincial Profile: Gauteng Community Survey 2016. Prov Profile Gauteng Community Surv 2016. 2018;(03-1–9):1–91.
- 14. KwaZulu-Natal Department of Health. Referral system: levels of care. 2014. p. 2017.
- 15. NHLS. 2017/18 NHLS Annual Report. Sandringham; 2018.
- 16. Parliament of the Republic of south Africa. Protection of Personal Information Act, 2013 Ensuring protection of your personal information and effective access to information. 2013;(4):154.
- 17. Bast M, Muller-Hermelink HK, Boilesen E, Armitage JO, MacLennan KA, Perry AM, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016;101(10):1244–50.

APPENDICES

Apendix 1: List of Data Sources

PUBLIC HOSPITALS

- Charlotte Maxeke Johannesburg Academic Hospital
- Chris Hani Baragwanath Academic Hospital
- Steve Biko Academic Hospital
- Tshwane District Hospital
- Pholosong Regional Hospital
- Far East Rand Regional Hospital
- Thelle Mogoerane Regional Hospital
- Tembisa Regional Hospital
- Tambo Memorial Regional Hospital
- Edenvale Hospital

PRIVATE HEALTH FACILITIES

- Benoni Oncology Centre
- Gauteng Prostate Oncology Morehill Clinic
- Sauteng Oncology Benoni Oncology Centre
- Gauteng Oncology Linmed Hospital
- Netcare Clinton Oncology

HOSPICES

- East Rand Hospice
- Flora Madiba Hospice
- Stepping Stone Hospice
- St Francis Hospice

SOUTH AFRICAN ONCOLOGY CONSORTIUM

Private Oncologists

PAEDIATRIC ONCOLOGY

- CHOC Childhood cancer foundation
- Chris Hani Baragwanath Academic Hospital
- Steve Biko Academic Hospital
- Donald Gordon Medical Oncology Unit

NHLS

CDW pathology based cancer reports

health Department: Health Republic of south Africa National Health Act, 2003 (Act No. 61 of 2003) Regulation Number 380	Republic of South Africa Department of Health CANCER REGISTRATION FORM	To be completed in duplicate in BLOCK LETTERS . Please mark with ⊠ the CORRECT box, where required. Original to be submitted to the National Cancer Register and copy to be retained: To be submitted to the National Cancer Register via: e-mail: cancer.registry@nhls.ac.za fax: 011 489 9132 / 011 489 9152
A. PARTICULARS OF INDIVIDUAL		Post: PO Box 1038. Johannesburg. 2000
1. Name of facility		
USE PATIENT STICKER if available		
2. Surname		
3. Full names		
4. Date of birth		
5. Folder number		
6. Sex Male		
7. ID number/Passport number		
8. Race group African	Coloured White Indian Other	
9. Area of residence		
9.1 City/town/village		
9.2 Postal code	9.3 How long at this address?	years
Please record place of birth if not the s	ame as current address	
9.4 City/town/village		
9.5 Postal code		
B. RISK FACTOR PROFILE		
10. Usual occupation of patient (If retired, give type of work done for most of	of working life)	
11. Type of industry/business (eg Mining, farming etc)		
12. Did the patient ever smoke tobacco?	Yes No Unknown	
13. Did the patient ever consume alcohol regular (that is, more than once a week)	ly? Yes No Unknown	
14. HIV status	Negative Positive Unknown	
C. CLINICAL AND LABORATORY DETAILS		
15. Date of diagnosis		
16. Cancer diagnosis and Histology Please give all information available on the site, lat	erality, histology and behaviour of the tumour	17. ICD-10
18. Grade Well differentiated	Moderately differentiated Poorly differentiated	Unknown/Not applicable
19. Stage Primary/localised	Metastatic Unknown/Not applicable	
20. Invasiveness In-situ	Invasive	
21. Basis of diagnosis	Clinical with investigation Cytology/histopathology	Molecular Death Certificate
22. Prescribed treatment Surgery	Radiation Chemotherapy Other Pa	lliation Alternative None
INFORMANT PARTICULARS		OFFICE CODING
Name (Print)		
MP/NC Number		M -
Signature	Date	

Apendix 2: South African Cancer Notification Form

Appendix 3: Tables of Incidence by site, sex, age group and population group Ekurhuleni 2017

Asian Fen	nales:	Crude and Age	Adjusted In	cidence Ra	ates/100 0	00	
Site	Ν	Mid-Year Population	Crude Incidence	ASR	95% LCL	95% UCL	SE
Breast	13	32371	40.16	41.57	21.71	72.52	12.43
Cervix	2	32371	6.18	4.99	0.50	21.69	5.34
Colorectal	1	32371	3.09	4.07	0.10	21.77	5.58
Non Hodgkin lymphoma	1	32371	3.09	4.07	0.10	21.77	5.58
Mouth	1	32371	3.09	3.11	0.08	19.15	4.92
Kaposi's Sarcoma	1	32371	3.09	3.10	0.08	19.12	4.91
Hodgkin lymphoma	1	32371	3.09	2.98	0.08	18.83	4.84
Myeloma	1	32371	3.09	2.44	0.06	17.52	4.52
Uterus	1	32371	3.09	2.36	0.06	17.35	4.48
Lung	1	32371	3.09	2.31	0.06	17.25	4.46
Brain, CNS	1	32371	3.09	1.97	0.05	16.53	4.29

Tables of ASR and Crude Incidence by population group

Black	Females	s: Crude and Ag	e-Adjusted I	ncidence R	ates/100 0	00	
Site	N	Mid-Year Population	Crude Incidence	ASR	95% LCL	95% UCL	SE
Cervix	448	1331741	33.64	34.56	31.28	38.09	1.72
Breast	365	1331741	27.41	29.99	26.84	33.41	1.66
Uterus	68	1331741	5.11	7.27	5.61	9.24	0.91
Colorectal	62	1331741	4.66	5.36	4.07	6.94	0.71
Oesophagus	27	1331741	2.03	2.81	1.84	4.08	0.56
Ovary	32	1331741	2.40	2.79	1.87	3.99	0.52
Vulva	39	1331741	2.93	2.60	1.83	3.62	0.44
Primary site unknown	26	1331741	1.95	2.36	1.51	3.51	0.49
Non Hodgkin Iymphoma	33	1331741	2.48	2.30	1.55	3.31	0.43
Lung	20	1331741	1.50	2.16	1.31	3.32	0.50
Kaposi's Sarcoma	31	1331741	2.33	1.93	1.29	2.81	0.37
Liver & Bile duct	18	1331741	1.35	1.62	0.94	2.59	0.40
Leukaemia	15	1331741	1.13	1.24	0.68	2.08	0.34
Skin other	12	1331741	0.90	0.99	0.50	1.78	0.31
Thyroid	14	1331741	1.05	0.97	0.51	1.70	0.29
Anus	13	1331741	0.98	0.97	0.49	1.73	0.30
Pancreas	9	1331741	0.68	0.89	0.40	1.70	0.32
Tongue	9	1331741	0.68	0.89	0.39	1.71	0.32
SCC of skin	11	1331741	0.83	0.84	0.40	1.56	0.28
Myeloma	8	1331741	0.60	0.82	0.34	1.61	0.31
Kidney	10	1331741	0.75	0.77	0.36	1.47	0.27
Other specified	9	1331741	0.68	0.73	0.32	1.43	0.27
Eye	10	1331741	0.75	0.73	0.34	1.40	0.26
Melanoma	7	1331741	0.53	0.71	0.28	1.46	0.29
BCC	8	1331741	0.60	0.70	0.29	1.41	0.27
Hodgkin lymphoma	11	1331741	0.83	0.70	0.33	1.32	0.24
Brain, CNS	8	1331741	0.60	0.68	0.29	1.36	0.26
Connective tissue	9	1331741	0.68	0.64	0.28	1.26	0.24
Ill defined	6	1331741	0.45	0.60	0.22	1.31	0.27
Bladder	5	1331741	0.38	0.55	0.18	1.26	0.27
Naso-Oropharynx	6	1331741	0.45	0.55	0.19	1.22	0.25
Stomach	6	1331741	0.45	0.53	0.19	1.18	0.24
Larynx	5	1331741	0.38	0.51	0.16	1.19	0.25
Vagina	7	1331741	0.53	0.46	0.18	1.02	0.21
Mouth	3	1331741	0.23	0.24	0.04	0.74	0.17
Bone	3	1331741	0.23	0.20	0.04	0.67	0.16
Endocrine	3	1331741	0.23	0.20	0.04	0.66	0.15
Salivary gland	2	1331741	0.15	0.17	0.02	0.66	0.16
Mesothelioma	1	1331741	0.08	0.11	0.00	0.58	0.15
Haematology other	2	1331741	0.15	0.11	0.01	0.50	0.12

Coloured	Female:	s: Crude and A	ge Adjusted	Incidence	Rates/100	000	
Site	Ν	Mid-Year Population	Crude Incidence	ASR	95% LCL	95% UCL	SE
Breast	10	44610	22.42	22.06	10.32	41.46	7.60
Cervix	5	44610	11.21	10.35	3.21	25.29	5.39
Lung	4	44610	8.97	7.11	1.85	19.96	4.43
Pancreas	3	44610	6.73	6.56	1.32	19.93	4.58
Colorectal	2	44610	4.48	5.49	0.60	19.50	4.73
Uterus	1	44610	2.24	3.45	0.09	16.67	4.26
Eye	1	44610	2.24	3.35	0.08	16.37	4.18
Connective tissue	1	44610	2.24	2.95	0.07	15.17	3.87
Non Hodgkin lymphoma	1	44610	2.24	2.66	0.07	14.34	3.66
SCC of skin	1	44610	2.24	2.66	0.07	14.34	3.66
Ovary	2	44610	4.48	2.47	0.30	12.44	3.06
Haematology other	1	44610	2.24	1.90	0.05	12.31	3.15
BCC	1	44610	2.24	1.86	0.05	12.20	3.12
Skin other	1	44610	2.24	1.33	0.03	11.00	2.84

Whit	e Female	s: Crude and A	ge Adjusted Ir	icidence l	Rates/100 (000	
Site	N	Mid-Year	Crude	ASR	95% LCL	95% UCL	SE
		Population	Incidence				
Breast	188	233632	80.47	48.65	41.61	56.73	3.77
Colorectal	44	233632	18.83	10.52	7.15	15.10	1.96
Lung	40	233632	17.12	7.65	5.33	11.01	1.39
Cervix	26	233632	11.13	6.88	4.39	10.54	1.51
Ovary	20	233632	8.56	5.79	3.15	9.81	1.64
BCC	21	233632	8.99	4.94	2.93	8.13	1.27
Melanoma	15	233632	6.42	3.89	2.11	6.91	1.17
Myeloma	12	233632	5.14	2.73	1.35	5.35	0.98
Non Hodgkin lymphoma	11	233632	4.71	2.65	1.27	5.28	0.98
Brain, CNS	10	233632	4.28	2.51	0.91	5.59	1.15
Pancreas	10	233632	4.28	2.47	1.15	5.06	0.96
Uterus	11	233632	4.71	2.17	1.03	4.54	0.86
Primary site unknown	11	233632	4.71	2.15	0.99	4.57	0.88
Liver & Bile duct	9	233632	3.85	1.84	0.79	4.17	0.83
SCC of skin	10	233632	4.28	1.58	0.72	3.70	0.74
Kidney	3	233632	1.28	1.47	0.20	4.64	1.12
Leukaemia	8	233632	3.42	1.44	0.58	3.58	0.74
Skin other	7	233632	3.00	1.36	0.49	3.55	0.76
Connective tissue	4	233632	1.71	1.27	0.32	3.69	0.84
Hodgkin lymphoma	4	233632	1.71	1.10	0.21	3.54	0.83
Endocrine	4	233632	1.71	1.06	0.27	3.28	0.75
Naso-Oropharynx	4	233632	1.71	0.97	0.21	3.21	0.75
Stomach	5	233632	2.14	0.92	0.27	2.96	0.68
Bone	3	233632	1.28	0.80	0.15	2.96	0.71
Thyroid	3	233632	1.28	0.78	0.13	2.95	0.71
Larynx	3	233632	1.28	0.74	0.13	2.87	0.69
Haematology other	3	233632	1.28	0.72	0.13	2.81	0.68
Ill defined	4	233632	1.71	0.71	0.19	2.66	0.63
Other specified	3	233632	1.28	0.67	0.12	2.72	0.66
Oesophagus	4	233632	1.71	0.60	0.16	2.49	0.60
Vulva	2	233632	0.86	0.55	0.06	2.60	0.65
Lip	2	233632	0.86	0.52	0.06	2.53	0.63
Bladder	2	233632	0.86	0.50	0.05	2.51	0.63
Tongue	2	233632	0.86	0.50	0.05	2.51	0.63
Vagina	1	233632	0.43	0.39	0.01	2.49	0.65
Mouth	2	233632	0.86	0.34	0.04	2.22	0.57
Small intestine	1	233632	0.43	0.17	0.00	2.04	0.54
Salivary gland	1	233632	0.43	0.17	0.00	2.03	0.54
Kaposi's Sarcoma	1	233632	0.43	0.15	0.00	2.00	0.54
Mesothelioma	1	233632	0.43	0.11	0.00	1.95	0.53

A	sian Male	es: Crude and Ag	ge Adjusted I	ncidence R	ates/100 0	00	
Site	Ν	Mid-Year Population	Crude Incidence	ASR	95% LCL	95% UCL	SE
Prostate	8	35011	22.85	26.20	11.11	55.12	10.89
Leukaemia	3	35011	8.57	9.56	1.72	33.25	8.00
Kaposi's Sarcoma	2	35011	5.71	5.32	0.50	26.65	6.79
Lung	2	35011	5.71	5.32	0.50	26.65	6.79
Oesophagus	1	35011	2.86	3.98	0.10	25.67	6.75
Liver & Bile duct	1	35011	2.86	3.98	0.10	25.67	6.75
Non Hodgkin							
lymphoma	1	35011	2.86	3.98	0.10	25.67	6.75
Haematology other	1	35011	2.86	3.72	0.09	25.05	6.59
Stomach	1	35011	2.86	3.72	0.09	25.05	6.59
Mouth	1	35011	2.86	3.72	0.09	25.05	6.59
Skin other	1	35011	2.86	3.72	0.09	25.05	6.59
Primary site							
unknown	1	35011	2.86	3.53	0.09	24.60	6.49
Other specified	1	35011	2.86	3.29	0.08	24.08	6.36
Brain, CNS	1	35011	2.86	2.87	0.07	23.18	6.15
Colorectal	1	35011	2.86	2.69	0.07	22.82	6.07

Bla	ack Males:	Crude and Ag	e Adjusted Iı	ncidence R	Rates/100 0	00	
Site	N	Mid-Year	Crude	ASR	95% LCL	95% UCL	SE
D		Population	Incidence	00.75	25.04	22.00	4.00
Prostate	235	1430318	16.43	28.75	25.01	32.86	1.98
Colorectal	39	1430318	2.73	3.90	2.65	5.50	0.71
Kaposi's Sarcoma	52	1430318	3.64	3.24	2.32	4.43	0.52
Lung	31	1430318	2.17	3.02	2.00	4.35	0.58
Oesophagus	31	1430318	2.17	2.66	1.77	3.84	0.51
Primary site unknown	27	1430318	1.89	2.39	1.50	3.61	0.52
Non Hodgkin lymphoma	37	1430318	2.59	2.32	1.58	3.33	0.43
SCC of skin	18	1430318	1.26	1.61	0.92	2.61	0.42
Stomach	17	1430318	1.19	1.44	0.80	2.40	0.39
Tongue	14	1430318	0.98	1.34	0.67	2.35	0.41
Naso-Oropharynx	13	1430318	0.91	1.34	0.69	2.33	0.40
Leukaemia	17	1430318	1.19	1.30	0.73	2.17	0.35
Larynx	12	1430318	0.84	1.24	0.62	2.19	0.39
Hodgkin lymphoma	16	1430318	1.12	1.15	0.63	1.96	0.33
Liver & Bile duct	13	1430318	0.91	1.00	0.51	1.81	0.32
Skin other	12	1430318	0.84	1.00	0.50	1.82	0.32
Mouth	11	1430318	0.77	0.97	0.47	1.80	0.33
Other specified	12	1430318	0.84	0.92	0.45	1.71	0.31
Ill defined	9	1430318	0.63	0.81	0.34	1.61	0.31
BCC	6	1430318	0.42	0.79	0.25	1.75	0.37
Myeloma	8	1430318	0.56	0.78	0.32	1.57	0.31
Pancreas	10	1430318	0.70	0.78	0.34	1.54	0.29
Eye	9	1430318	0.63	0.70	0.30	1.42	0.27
Melanoma	8	1430318	0.56	0.68	0.28	1.40	0.27
Salivary gland	6	1430318	0.42	0.67	0.20	1.54	0.33
Anus	9	1430318	0.63	0.63	0.24	1.35	0.27
Kidney	7	1430318	0.49	0.57	0.22	1.25	0.25
Connective tissue	7	1430318	0.49	0.54	0.21	1.19	0.24
Haematology other	6	1430318	0.42	0.41	0.13	1.01	0.21
Penis	7	1430318	0.49	0.41	0.16	0.95	0.19
Brain, CNS	5	1430318	0.35	0.40	0.12	1.01	0.22
Bone	5	1430318	0.35	0.37	0.11	0.95	0.21
Bladder	4	1430318	0.28	0.36	0.08	1.02	0.23
Breast	5	1430318	0.35	0.36	0.11	0.93	0.20
Testis	3	1430318	0.21	0.30	0.06	0.89	0.21
Mesothelioma	2	1430318	0.14	0.19	0.02	0.72	0.18
Thyroid	3	1430318	0.14	0.17	0.02	0.63	0.15
Gum	1	1430318	0.21	0.13	0.00	0.66	0.13
Lip	1	1430318	0.07	0.13	0.00	0.54	0.17
Small intestine	1	1430318	0.07	0.08	0.00	0.54	0.14
Burkitt lymphoma	1	1430318	0.07	0.07	0.00	0.31	0.13
Endocrine	1	1430318		0.05	0.00	0.46	0.12
LINUULIIIE	L	1430310	0.07	0.04	0.00	0.40	0.12

Color	ured Males	: Crude and Ag	ge Adjusted I	ncidence	Rates/100	000	
Site	N	Mid-Year Population	Crude Incidence	ASR	95% LCL	95% UCL	SE
Prostate	6	41212	14.56	27.89	6.74	68.52	15.56
Colorectal	2	41212	4.85	9.41	1.14	32.83	8.03
Lung	2	41212	4.85	9.21	0.84	33.73	8.39
Leukaemia	2	41212	4.85	7.04	0.71	27.85	6.91
Non Hodgkin Iymphoma	3	41212	7.28	5.81	1.17	23.23	5.63
Primary site unknown	1	41212	2.43	4.71	0.12	25.05	6.51
Pancreas	1	41212	2.43	4.71	0.12	25.05	6.51
Larynx	2	41212	4.85	3.85	0.38	21.00	5.35
Eye	1	41212	2.43	2.81	0.07	20.20	5.30
Breast	1	41212	2.43	2.33	0.06	19.17	5.06
Skin other	1	41212	2.43	2.33	0.06	19.17	5.06
Ill defined	1	41212	2.43	1.92	0.05	18.38	4.89
Mouth	1	41212	2.43	1.60	0.04	17.84	4.77
Brain, CNS	1	41212	2.43	1.60	0.04	17.84	4.77

		s: Crude and Ag Mid-Year	Crude				
Site	N	Population	Incidence	ASR	95% LCL	95% UCL	SE
Prostate	222	230209	96.43	48.97	42.28	56.65	3.57
Colorectal	62	230209	26.93	14.26	10.81	18.77	1.95
BCC	48	230209	20.85	11.75	8.58	16.01	1.82
Lung	36	230209	15.64	7.72	5.33	11.20	1.43
Melanoma	27	230209	11.73	5.88	3.80	9.09	1.29
Oesophagus	16	230209	6.95	5.05	2.54	9.04	1.60
Primary site unknown	22	230209	9.56	4.94	3.01	8.03	1.22
Non Hodgkin lymphoma	18	230209	7.82	4.91	2.80	8.27	1.34
Leukaemia	14	230209	6.08	4.86	2.33	8.93	1.63
Bladder	15	230209	6.52	3.69	2.00	6.60	1.12
Stomach	14	230209	6.08	3.60	1.84	6.63	1.17
Pancreas	15	230209	6.52	3.43	1.87	6.19	1.05
Brain, CNS	14	230209	6.08	3.16	1.69	5.85	1.02
Hodgkin lymphoma	7	230209	3.04	2.74	1.04	5.96	1.21
Kidney	11	230209	4.78	2.57	1.26	5.12	0.94
Skin other	11	230209	4.78	2.40	1.16	4.87	0.91
SCC of skin	10	230209	4.34	2.34	1.09	4.85	0.92
Myeloma	10	230209	4.34	2.01	0.94	4.32	0.83
Testis	4	230209	1.74	1.66	0.43	4.47	1.00
Other specified	7	230209	3.04	1.65	0.64	3.99	0.82
Anus	6	230209	2.61	1.64	0.58	4.08	0.86
Naso-Oropharynx	5	230209	2.17	1.37	0.40	3.76	0.83
Bone	3	230209	1.30	1.16	0.18	3.81	0.91
Larynx	4	230209	1.74	1.08	0.28	3.31	0.75
Connective tissue	4	230209	1.74	0.99	0.26	3.15	0.72
Mouth	4	230209	1.74	0.87	0.22	2.95	0.68
Liver & Bile duct	4	230209	1.74	0.82	0.21	2.84	0.66
Mesothelioma	4	230209	1.74	0.71	0.19	2.68	0.63
Breast	3	230209	1.30	0.66	0.13	2.67	0.65
Salivary gland	3	230209	1.30	0.66	0.13	2.67	0.65
Endocrine	2	230209	0.87	0.60	0.07	2.69	0.67
Ill defined	3	230209	1.30	0.60	0.12	2.56	0.62
Penis	2	230209	0.87	0.48	0.05	2.47	0.62
Kaposi's Sarcoma	2	230209	0.87	0.45	0.04	2.43	0.61
Eye	1	230209	0.43	0.31	0.01	2.28	0.60
Tongue	1	230209	0.43	0.30	0.01	2.28	0.59
Lip	1	230209	0.43	0.18	0.00	2.04	0.54

										Α	ll Mal	es											
Site	All Ages	Known Age	Unknown Age	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	LR74	ICD 10
All sites	1414	1357	57	11.2	8.8	7.9	6.1	4.1	15.7	27.4	38.7	49.1	86.8	145.5	212.7	388.0	459.0	629.6	654.6	734.0	602.5	10	
All sites but C44	1307	1251	56	11.2	8.8	7.9	5.2	4.1	15.1	26.7	37.4	45.8	78.9	125.6	198.0	361.4	415.3	594.0	620.1	622.8	558.4	11	
Lip	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	3.2	0.0	0.0	0.0	4260	C00
Tongue	15	14	1	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	2.0	3.7	0.0	3.8	8.7	0.0	0.0	0.0	14.7	972	C02
Gum	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	6195	C03
Mouth	17	17	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	3.0	3.7	1.5	7.6	4.4	3.2	5.7	0.0	0.0	801	C06
Salivary gland	9	8	1	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	1.2	2.9	0.0	2.2	6.5	0.0	0.0	14.7	1402	C07
Naso-Oropharynx	18	17	1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.6	0.0	1.0	7.5	0.0	7.6	2.2	6.5	5.7	11.1	0.0	768	C11
Oesophagus	48	43	5	0.7	0.0	0.0	0.0	0.0	0.0	1.4	0.6	0.8	6.9	8.7	10.3	9.5	15.3	12.9	17.2	11.1	29.4	298	C15
Stomach	32	28	4	0.0	0.0	0.0	0.0	0.0	0.6	0.7	0.6	2.5	3.0	2.5	2.9	9.5	10.9	22.6	5.7	0.0	14.7	359	C16
Small intestine	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16079	C17
Colorectal	103	94	9	0.0	0.0	0.0	0.0	0.0	1.2	2.8	1.9	1.6	7.9	7.5	22.0	26.6	45.9	29.1	45.9	89.0	58.8	137	C18
Anus	15	15	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	1.6	2.0	0.0	0.0	3.8	6.6	0.0	0.0	11.1	29.4	1258	C21
Liver & Bile duct	18	16	2	0.0	0.0	0.0	0.0	0.0	1.8	0.7	0.0	1.6	1.0	0.0	4.4	3.8	8.7	3.2	5.7	0.0	0.0	791	C22
Pancreas	25	20	5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	3.0	2.5	2.9	7.6	6.6	19.4	5.7	0.0	0.0	435	C25
Larynx	18	17	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	2.5	5.9	11.4	6.6	3.2	5.7	0.0	0.0	663	C32
Lung	70	65	5	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	2.5	1.0	10.0	19.1	13.3	24.0	35.5	57.4	55.6	14.7	189	C34
Bone	8	8	0	0.0	0.0	0.9	0.9	0.7	0.0	0.0	1.3	0.0	1.0	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	2204	C41
Melanoma	35	34	1	0.0	0.0	0.9	0.0	0.0	0.6	0.0	0.0	1.6	1.0	5.0	2.9	7.6	10.9	22.6	28.7	22.2	14.7	377	C43
SCC of skin	28	28	0	0.0	0.0	0.0	0.9	0.0	0.0	0.7	0.0	1.6	1.0	8.7	2.9	1.9	13.1	3.2	11.5	33.4	14.7	587	C44
BCC	54	54	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.6	5.9	6.2	8.8	17.1	19.7	22.6	11.5	55.6	29.4	243	C44
Skin other	25	24	1	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.6	0.0	1.0	5.0	4.4	7.6	8.7	9.7	11.5	22.2	0.0	532	C44

Age Specific Incidence Rates /100 000 and Lifetime Risk reported as 1: x

Mesothelioma	6	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	2.2	3.2	11.5	0.0	0.0	2396	C45
Kaposi's Sarcoma	56	55	1	0.0	0.0	0.0	0.0	0.7	0.6	8.4	8.4	6.5	6.9	5.0	1.5	5.7	4.4	0.0	23.0	0.0	0.0	417	C46
Connective tissue	11	11	0	1.4	0.0	0.0	0.0	0.0	0.6	0.7	0.0	0.0	0.0	2.5	0.0	3.8	2.2	3.2	0.0	11.1	0.0	1389	C49
Breast	9	9	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	2.0	2.5	1.5	0.0	2.2	6.5	0.0	0.0	0.0	1315	C50
Penis	9	8	1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.6	0.8	2.0	2.5	0.0	1.9	2.2	0.0	0.0	0.0	0.0	1868	C60
Prostate	471	462	9	0.7	0.0	0.0	0.0	0.0	0.6	0.7	0.6	0.8	17.7	22.4	73.3	178.8	177.1	329.3	321.6	289.2	308.6	25	C61
Testis	7	7	0	1.4	0.0	0.0	0.0	0.0	0.6	0.7	1.3	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	3238	C62
Other specified	20	20	0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.3	1.6	0.0	3.7	4.4	3.8	6.6	6.5	11.5	0.0	0.0	700	C63
Kidney	18	17	1	0.7	1.6	0.0	0.0	0.0	0.0	0.0	0.0	1.6	1.0	1.2	5.9	3.8	4.4	6.5	0.0	11.1	0.0	750	C64
Bladder	19	18	1	0.0	0.0	0.9	0.0	0.7	0.0	0.0	1.3	0.0	0.0	0.0	0.0	5.7	6.6	3.2	17.2	22.2	44.1	1091	C67
Eye	11	11	0	2.8	0.0	0.9	0.0	0.0	0.6	0.0	1.3	0.0	1.0	1.2	0.0	1.9	0.0	0.0	0.0	0.0	0.0	2063	C69
Brain, CNS	21	18	3	0.0	1.6	0.0	0.0	0.0	0.6	0.0	0.6	0.8	1.0	2.5	2.9	3.8	6.6	9.7	5.7	11.1	14.7	664	C71
Thyroid	3	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7644	C73
Endocrine	3	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.0	0.0	4439	C74
III defined	13	13	0	0.0	0.0	0.0	0.9	0.7	0.0	0.0	0.6	0.0	0.0	3.7	2.9	1.9	6.6	0.0	5.7	0.0	0.0	1155	C76
Primary site unknown	51	50	1	0.0	0.8	0.0	0.0	0.7	0.6	0.7	0.6	1.6	4.9	8.7	4.4	15.2	10.9	22.6	23.0	33.4	29.4	279	C80
Hodgkin lymphoma	23	23	0	0.0	1.6	0.0	3.5	0.0	1.8	2.1	1.3	1.6	1.0	0.0	2.9	5.7	0.0	3.2	0.0	0.0	0.0	808	C81
Burkitt lymphoma	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24457	C83
NHL	59	58	1	0.0	0.0	1.8	0.0	0.7	3.6	1.4	5.2	8.2	6.9	5.0	10.3	5.7	2.2	9.7	17.2	22.2	0.0	331	C84
Myeloma	18	17	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	4.4	1.9	10.9	12.9	5.7	0.0	0.0	587	C90
Leukaemia	36	34	2	2.1	3.2	0.9	0.0	0.0	0.6	1.4	1.3	2.5	0.0	2.5	5.9	11.4	0.0	9.7	5.7	11.1	44.1	484	C92
Haematology other	7	7	0	0.7	0.0	0.0	0.0	0.0	0.0	0.7	1.3	0.0	0.0	1.2	0.0	1.9	2.2	0.0	0.0	0.0	0.0	2493	C96

											All F	emales											
Site	All Ages	Known Age	Unknown Age	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	LR74	ICD 10
All sites	1957	1904	53	15.3	2.3	7.1	7.1	13.1	27.2	76.3	92.4	143.1	179.9	223.6	316.4	466.1	359.2	472.2	724.2	1059.7	1134.9	9	
All sites but C44	1885	1834	51	15.3	2.3	6.2	6.2	12.5	26.7	74.4	90.2	137.7	176.5	214.7	312.0	443.6	346.3	450.8	663.9	1021.9	996.5	9	
Lip	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	2.0	0.0	0.0	0.0	0.0	0.0	5700	C00
Tongue	11	11	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	1.7	2.2	0.0	2.0	2.2	7.2	15.1	0.0	0.0	1264	C02
Mouth	6	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.8	0.0	0.0	2.0	2.2	7.2	0.0	0.0	0.0	1569	C06
Salivary gland	3	3	0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	3.6	0.0	0.0	0.0	3183	C07
Naso-Oropharynx	10	10	0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.7	0.8	0.0	0.0	4.1	2.2	0.0	7.5	18.9	27.7	2217	C11
Oesophagus	31	30	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.7	2.2	4.4	10.2	17.2	21.5	7.5	37.8	27.7	346	C15
Stomach	11	10	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	4.5	0.0	2.0	4.3	3.6	0.0	18.9	27.7	1328	C16
Small intestine	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	9299	C17
Colorectal	110	104	6	1.4	0.0	0.0	0.0	1.3	0.0	3.8	2.3	5.4	5.9	12.3	24.9	28.6	34.4	28.6	45.3	75.7	110.7	135	C18
Anus	13	13	0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.1	3.4	0.8	0.0	1.5	0.0	0.0	0.0	7.5	37.8	0.0	2693	C21
Liver & Bile duct	27	26	1	0.0	0.0	0.0	0.0	0.7	0.0	0.6	0.0	1.3	2.5	4.5	4.4	8.2	4.3	17.9	15.1	0.0	0.0	451	C22
Pancreas	23	23	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	6.7	2.9	10.2	6.5	3.6	7.5	18.9	27.7	634	C25
Larynx	8	8	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	1.1	1.5	0.0	0.0	7.2	15.1	0.0	0.0	1752	C32
Lung	65	59	6	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	1.7	3.4	11.7	14.3	23.7	46.5	67.9	94.6	83.0	193	C34
Bone	6	6	0	0.7	0.0	0.0	0.0	0.0	0.0	0.6	0.0	1.3	0.0	0.0	1.5	0.0	2.2	0.0	0.0	0.0	0.0	3179	C41
Melanoma	22	21	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.3	3.4	1.1	2.9	10.2	10.8	0.0	7.5	0.0	27.7	661	C43
BCC	30	29	1	0.0	0.0	0.0	0.9	0.0	0.0	1.3	0.6	2.0	1.7	2.2	0.0	14.3	8.6	14.3	22.6	0.0	27.7	436	C44
Skin other	22	19	1	0.0	0.0	0.9	0.0	0.7	0.0	0.6	0.0	2.7	0.8	3.4	1.5	2.0	6.5	0.0	15.1	18.9	27.7	1052	C44
SCC of skin	20	22	0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	1.7	0.7	0.8	1.1	2.9	6.1	0.0	7.2	30.2	18.9	83.0	949	C44
Mesothelioma	2	1	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	7.5	0.0	0.0	5591	C45
Kaposi's Sarcoma	33	33	0	0.0	0.0	0.9	0.0	2.0	2.8	5.1	1.7	3.4	1.7	3.4	1.5	0.0	0.0	3.6	0.0	0.0	27.7	774	C46

Connective tissue	14	14	0	1.4	0.0	0.0	0.9	0.0	0.6	0.6	0.6	3.4	0.8	0.0	1.5	0.0	2.2	0.0	0.0	0.0	0.0	1689	C49
Breast	576	562	14	0.7	0.0	0.0	0.9	0.7	7.8	15.9	27.6	47.0	70.6	67.1	99.6	143.1	105.4	118.1	203.7	264.9	276.8	29	C50
Vulva	41	41	0	0.0	0.0	0.0	0.9	0.0	1.1	1.9	5.1	5.4	7.6	5.6	4.4	0.0	2.2	0.0	0.0	0.0	0.0	588	C51
Vagina	8	8	0	0.0	0.0	0.0	0.0	0.0	0.6	0.6	0.6	2.0	0.8	0.0	0.0	0.0	0.0	3.6	0.0	0.0	0.0	2443	C52
Cervix	481	476	5	1.4	0.0	0.0	0.9	0.0	6.1	29.9	34.9	49.7	55.5	61.5	80.6	90.0	51.6	68.0	90.5	113.5	83.0	38	C53
Uterus	81	79	2	1.4	0.0	0.0	0.0	0.0	0.0	0.6	1.1	1.3	0.8	2.2	14.6	38.8	23.7	42.9	52.8	170.3	83.0	157	C54
Ovary	54	49	5	0.7	0.0	0.0	0.9	2.0	1.1	0.6	1.7	1.3	5.0	6.7	10.3	16.4	8.6	7.2	22.6	56.8	55.4	321	C56
Other specified	12	12	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.8	2.2	2.9	6.1	2.2	0.0	7.5	0.0	0.0	1298	C63
Kidney	13	13	0	1.4	1.6	0.9	0.0	0.7	0.0	0.0	1.1	0.0	0.8	2.2	2.9	0.0	0.0	0.0	0.0	0.0	0.0	1721	C64
Bladder	7	6	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.5	0.0	6.5	3.6	0.0	18.9	0.0	1622	C67
Еуе	11	11	0	0.7	0.8	0.0	0.0	0.0	0.0	1.3	0.6	1.3	0.0	2.2	1.5	0.0	2.2	0.0	0.0	0.0	0.0	1904	C69
Brain, CNS	19	18	1	1.4	0.0	0.9	0.0	0.7	0.0	0.0	0.6	0.0	2.5	0.0	2.9	6.1	4.3	3.6	7.5	37.8	0.0	872	C71
Thyroid	17	16	1	0.0	0.0	0.0	0.0	0.0	1.7	1.3	1.7	0.7	0.0	3.4	1.5	4.1	4.3	0.0	0.0	0.0	0.0	1081	C73
Endocrine	7	7	0	0.0	0.0	0.0	0.0	0.7	0.6	0.0	0.6	0.0	0.0	1.1	1.5	2.0	0.0	0.0	0.0	0.0	27.7	3124	C74
III defined	10	10	0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	2.0	4.3	3.6	0.0	0.0	55.4	1316	C76
Primary site unknown	38	38	0	0.7	0.0	0.0	0.0	0.0	0.0	2.5	1.1	0.7	1.7	3.4	2.9	18.4	8.6	10.7	22.6	37.8	27.7	395	C80
Hodgkin lymphoma	16	16	0	0.0	0.0	0.9	0.0	1.3	1.1	1.9	1.1	0.0	1.7	0.0	1.5	2.0	0.0	3.6	7.5	0.0	0.0	1324	C81
NHL	46	46	0	0.0	0.0	0.9	0.0	0.7	0.6	3.8	3.9	2.7	2.5	7.8	4.4	6.1	8.6	14.3	15.1	0.0	0.0	356	C84
Myeloma	21	19	2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.8	3.4	4.4	6.1	2.2	14.3	22.6	18.9	27.7	630	C90
Leukaemia	23	20	3	1.4	0.0	1.8	0.9	0.7	1.1	0.6	0.0	0.0	0.8	3.4	2.9	4.1	2.2	7.2	7.5	18.9	27.7	742	C92
Haematology other	6	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.7	1.7	0.0	0.0	2.0	0.0	0.0	0.0	18.9	0.0	4032	C96

												Asia	n Fema	ales									
Site	All Ages	Known Age	Unknown Age	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	LR74	ICD10
All sites	24	22	2	0.0	0.0	0.0	0.0	38.7	0.0	27.1	65.8	77.1	99.4	201.5	0.0	203.5	517.8	243.5	894.4	943.3	0.0	14	
All sites but C44	24	22	2	0.0	0.0	0.0	0.0	38.7	0.0	27.1	65.8	77.1	99.4	201.5	0.0	203.5	517.8	243.5	894.4	943.3	0.0	14	
Mouth	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	103.6	0.0	0.0	0.0	0.0	194	C06
Colorectal	1	0	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	471.6	0.0		C18
Lung	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	38.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	519	C34
Kaposi's Sarcoma	1	1	0	0.0	0.0	0.0	0.0	38.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	517	C46
Breast	13	12	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32.9	38.6	49.7	134.3	0.0	101.8	414.2	121.8	894.4	0.0	0.0	23	C50
Cervix	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	27.1	0.0	0.0	0.0	67.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	213	C53
Uterus	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	471.6	0.0		C54
Brain, CNS	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	608	C71
Hodgkin lymphoma	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	49.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	403	C81
Non Hodgkin lymphoma	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	101.8	0.0	0.0	0.0	0.0	0.0	197	C84
Myeloma	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	121.8	0.0	0.0	0.0	165	C90

											Black F	emales											
Site	All Ages	Known Age	Unknown Age	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	LR74	ICD 10
All sites but C44	1356	1347	9	15.1	0.9	6.1	6.2	12.5	32.0	86.4	113.5	174.3	208.3	239.5	292.1	393.3	354.0	369.8	624.7	756.0	436.6	9	
All sites	1387	1378	9	15.1	0.9	7.1	7.2	13.3	32.7	88.0	115.8	179.3	210.9	246.2	294.2	410.0	361.8	375.4	637.7	756.0	436.6	9	
Tongue	9	9	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.3	3.3	0.0	2.8	3.9	5.6	26.0	0.0	0.0	1132	C02
Mouth	3	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.3	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	4117	C06
Salivary gland	2	2	0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.0	4363	C07
Naso- Oropharynx	6	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.0	1.3	0.0	0.0	2.8	3.9	0.0	13.0	0.0	0.0	2043	C11
Oesophagus	27	27	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	2.6	3.3	6.3	13.9	31.1	22.4	0.0	47.3	0.0	249	C15
Stomach	6	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	5.0	0.0	2.8	0.0	5.6	0.0	0.0	0.0	1391	C16
Colorectal	63	62	1	0.8	0.0	0.0	0.0	1.6	0.0	3.3	3.1	6.0	6.4	15.0	23.0	22.3	23.3	11.2	26.0	70.9	0.0	173	C18
Anus	13	13	0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	1.6	5.0	1.3	0.0	2.1	0.0	0.0	0.0	13.0	47.3	0.0	1858	C21
Liver & Bile duct	18	18	0	0.0	0.0	0.0	0.0	0.8	0.0	0.8	0.0	2.0	2.6	5.0	2.1	11.2	3.9	16.8	0.0	0.0	0.0	444	C22
Pancreas	10	10	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.7	2.1	2.8	3.9	0.0	13.0	23.6	31.2	1298	C25
Larynx	5	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	2.1	0.0	0.0	11.2	13.0	0.0	0.0	1372	C32
Lung	20	20	0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.7	6.3	8.4	7.8	28.0	52.1	0	0	370	C34
Bone	3	3	0	0.8	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7636	C41
Melanoma	7	6	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	8.4	7.8	5.6	0.0	0.0	0.0	840	C43
BCC	8	8	0	0.0	0.0	0.0	1.0	0.0	0.0	0.8	0.0	1.0	1.3	1.7	0.0	5.6	3.9	0.0	0.0	0.0	0.0	1310	C44
Skin other	12	12	0	0.0	0.0	1.0	0.0	0.8	0.0	0.8	0.0	3.0	0.0	3.3	2.1	2.8	3.9	0.0	13.0	0.0	0.0	1129	C44
SCC of skin	11	11	0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	2.3	1.0	1.3	1.7	0.0	8.4	0.0	5.6	0.0	0.0	0.0	954	C44
Mesothelioma	1	0	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19968	C45
Kaposi's Sarcoma	31	31	0	0.0	0.0	1.0	0.0	1.6	3.5	6.6	2.3	5.0	2.6	5.0	2.1	0.0	0.0	5.6	0.0	0.0	0.0	568	C46
Connective tissue	9	9	0	1.6	0.0	0.0	0.0	0.0	0.7	0.8	0.0	3.0	1.3	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	2109	C49
Breast	367	364	3	1.6	0.0	0.0	1.0	0.8	9.7	15.6	33.7	56.1	73.3	68.2	64.7	103.2	89.5	67.2	221.2	189.0	155.9	35	C50

	T	1	1	1	1	1	r		r	r	r		r	1	1	1			1			1	
Vulva	39	39	0	0.0	0.0	0.0	1.0	0.0	1.4	2.5	6.3	8.0	11.6	8.3	4.2	0.0	3.9	0.0	0.0	0.0	0.0	425	C51
Vagina	7	7	0	0.0	0.0	0.0	0.0	0.0	0.7	0.8	0.8	2.0	1.3	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.0	2110	C52
Cervix	448	448	0	1.6	0.0	0.0	1.0	0.0	7.6	37.8	45.4	71.1	78.4	79.8	108.5	114.4	81.7	106.5	117.1	118.1	93.6	28	C53
Uterus	67	66	1	1.6	0.0	0.0	0.0	0.0	0.0	0.8	1.6	2.0	1.3	5.0	16.7	41.8	31.1	56.0	65.1	165.4	93.6	127	C54
Ovary	32	30	2	0	0	0	1.03	3.12	1.39	0.82	1.57	1.00	3.86	6.65	10.43	8.37	3.89	5.60	26.03	47.25	0	419	C56
Other specified	9	9	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	1.3	3.3	4.2	2.8	3.9	0.0	0.0	0.0	0.0	1175	C63
Kidney	10	10	0	1.6	0.9	1.0	0.0	0.8	0.0	0.0	1.6	0.0	1.3	1.7	2.1	0.0	0.0	0.0	0.0	0.0	0.0	1834	C64
Bladder	5	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	11.7	0.0	0.0	23.6	0.0	1454	C67
Eye	10	10	0	0.8	0.0	0.0	0.0	0.0	0.0	1.6	0.8	2.0	0.0	3.3	2.1	0.0	3.9	0.0	0.0	0.0	0.0	1377	C69
Brain, CNS	9	9	0	1.6	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	3.9	0.0	2.1	2.8	3.9	0.0	0.0	0.0	0.0	1334	C71
Thyroid	14	14	0	0.0	0.0	0.0	0.0	0.0	2.1	0.8	2.3	1.0	0.0	5.0	2.1	5.6	0.0	0.0	0.0	0.0	0.0	1058	C73
Endocrine	3	3	0	0.0	0.0	0.0	0.0	0.8	0.7	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	5615	C74
Ill defined	6	6	0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	2.8	7.8	0.0	0.0	0.0	0.0	1269	C76
Primary site	28	28	0	0.8	0.0	0.0	0.0	0.0	0.0	3.3	1.6	0.0	2.6	3.3	4.2	22.3	7.8	5.6	13.0	23.6	62.4	389	C80
unknown																							
Hodgkin	11	11	0	0.0	0.0	1.0	0.0	0.8	1.4	2.5	1.6	0.0	1.3	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	1771	C81
lymphoma																							
Non Hodgkin	33	33	0	0.0	0.0	1.0	0.0	0.8	0.7	4.9	5.5	4.0	2.6	5.0	6.3	2.8	7.8	11.2	0.0	0.0	0.0	381	C84
lymphoma																							
Myeloma	8	8	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.7	4.2	0.0	3.9	5.6	26.0	0.0	0.0	1204	C90
Leukaemia	15	15	0	1.6	0.0	2.0	1.0	0.8	1.4	0.8	0.0	0.0	1.3	3.3	2.1	5.6	0.0	0.0	0.0	0.0	0.0	1004	C92
Haematology	2	2	0	0	0	0	0	0	0	0	0.78	1.00	0	0	0	0	0	0	0	0	0	11209	C96
other																							
																							1

										Colo	ured Fe	emales											
Site	All Ages	Known Age	Unknown Age	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	LR74	ICD10
All sites but C44	30	30	0	0.0	33.5	0.0	32.8	33.9	0.0	30.6	19.0	66.5	63.5	148.9	204.4	199.4	166.9	517.1	532.5	0.0	489.4	14	
All sites	33	33	0	0.0	33.5	0.0	32.8	33.9	0.0	30.6	19.0	88.6	63.5	186.1	204.4	199.4	166.9	517.1	798.7	0.0	489.4	13	
Colorectal	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	51.1	0.0	0.0	172.4	0.0	0.0	0.0	90	C18
Pancreas	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	51.1	66.5	0.0	0.0	0.0	0.0	0.0	171	C25
Lung	4	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.2	0.0	0.0	0.0	0.0	111.3	0.0	0.0	0.0	489.4	150	C34
BCC	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	37.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	538	C44
SCC of skin	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	266.2	0.0	0.0		C44
Skin other	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	903	C44
Connective tissue	1	1	0	0.0	0.0	0.0	32.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	611	C49
Breast	10	10	0	0.0	0.0	0.0	0.0	33.9	0.0	0.0	0.0	0.0	31.7	111.7	102.2	66.5	55.6	172.4	0.0	0.0	0.0	35	C50
Cervix	5	5	0	0.0	0.0	0.0	0.0	0.0	0.0	30.6	0.0	22.2	0.0	37.2	0.0	66.5	0.0	0.0	266.2	0.0	0.0	128	C53
Uterus	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	172.4	0.0	0.0	0.0	117	C54
Ovary	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.0	22.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	487	C56
Еуе	1	1	0	0.0	33.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	598	C69
NHL	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	266.2	0.0	0.0		C84
Haematology other	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	631	C96

										Wh	ite Fer	nales											
Site	All Ages	Known Age	Unknown Age	0-	5-	10-	15-	20-	25-	0-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	LR74	ICD10
All sites but C44	475	435	40	26.9	9.2	9.4	0.0	7.2	13.1	71.4	63.1	169.5	237.9	254.7	408.8	498.6	358.9	469.1	394.2	459.4	629.8	8	
All sites	513	471	42	26.9	9.2	9.4	0.0	7.2	13.1	78.6	68.4	182.6	248.7	273.4	420.7	533.7	382.0	511.7	459.9	505.3	779.7	8	
Lip	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	7.0	0.0	0.0	0.0	0.0	0.0	1545	C00
Tongue	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.0	0.0	8.5	0.0	0.0	0.0	1436	C02
Mouth	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.1	0.0	0.0	0.0	1173	C06
Salivary gland	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.5	0.0	0.0	0.0	2346	C07
Naso-Oropharynx	4	4	0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0	7.0	0.0	0.0	0.0	23.0	30.0	1412	C11
Oesophagus	4	3	1	0.0	0.0	0.0	0.0	0.0	6.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.1	10.9	0.0	0.0	848	C15
Stomach	5	4	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.4	0.0	0.0	11.6	0.0	0.0	0.0	30.0	834	C16
Small intestine	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	0.0	0.0	0.0	0.0	3456	C17
Colorectal	44	40	4	9.0	0.0	0.0	0.0	0.0	0.0	14.3	0.0	13.0	10.8	18.6	35.6	42.1	52.1	42.6	32.8	45.9	90.0	84	C18
Liver & Bile duct	9	8	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	12.4	11.9	0.0	5.8	8.5	21.9	0.0	0.0	455	C22
Pancreas	11	11	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.8	12.4	0.0	21.1	11.6	8.5	0.0	0.0	30.0	311	C25
Larynx	3	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	6.2	0.0	0.0	0.0	0.0	10.9	0.0	0.0	1722	C32
Lung	40	34	6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	5.4	0.0	29.6	35.1	34.7	76.8	65.7	137.8	30.0	107	C34
Bone	3	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	0.0	5.9	0.0	5.8	0.0	0.0	0.0	0.0	1097	C41
Melanoma	15	15	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	6.5	21.6	6.2	5.9	14.0	17.4	0.0	10.9	0.0	30.0	260	C43
BCC	21	20	1	0.0	0.0	0.0	0.0	0.0	0.0	7.1	5.3	13.0	5.4	6.2	0.0	35.1	17.4	34.1	21.9	0.0	30.0	162	C44
SCC of skin	10	10	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.9	0.0	0.0	8.5	32.8	23.0	90.0	982	C44
Skin other	7	6	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	12.4	0.0	0.0	5.8	0.0	10.9	23.0	30.0	847	C44
Mesothelioma	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.9	0.0	0.0		C45
Kaposi's Sarcoma	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	30.0		C46
Connective tissue	4	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	13.0	0.0	0.0	0.0	0.0	5.8	0.0	0.0	0.0	0.0	831	C49

Breast	186	176	10	9.0	0.0	0.0	0.0	0.0	6.5	42.9	21.0	91.3	124.4	93.2	219.2	217.7	121.5	162.0	76.6	114.8	60.0	19	C50
Vulva	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	1788	C51
Vagina	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3068	C52
Cervix	26	21	5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.8	13.0	21.6	24.9	23.7	21.1	17.4	0.0	21.9	23.0	0.0	146	C53
Uterus	12	11	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.9	14.0	17.4	8.5	32.8	23.0	0.0	387	C54
Ovary	20	17	3	9.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.2	18.6	17.8	35.1	11.6	0.0	10.9	0.0	60.0	185	C56
Other specified	3	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.0	0.0	0.0	10.9	0.0	0.0	1425	C63
Kidney	3	3	0	0.0	9.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.2	5.9	0.0	0.0	0.0	0.0	0.0	0.0	939	C64
Bladder	2	1	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.1	0.0	0.0	0.0	1173	C67
Brain, CNS	9	8	1	0.0	0.0	9.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	14.0	5.8	8.5	10.9	23.0	30.0	458	C71
Thyroid	3	2	1	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	5.8	8.5	0.0	0.0	0.0	932	C73
Endocrine	4	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	6.2	0.0	7.0	0.0	0.0	0.0	0.0	30.0	1082	C74
Ill defined	4	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	0.0	0.0	8.5	0.0	0.0	60.0	1384	C76
Primary site unknown	10	10	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	6.2	0.0	7.0	11.6	17.1	21.9	23.0	0.0	414	C80
Hodgkin lymphoma	4	4	0	0.0	0.0	0.0	0.0	7.2	0.0	0.0	0.0	0.0	0.0	0.0	5.9	0.0	0.0	8.5	10.9	0.0	0.0	923	C81
NHL	11	11	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	24.9	0.0	7.0	11.6	17.1	10.9	0.0	0.0	304	C84
Myeloma	12	10	2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	6.2	11.9	21.1	0.0	8.5	10.9	23.0	60.0	378	C90
Leukaemia	8	5	3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	0.0	0.0	7.0	5.8	17.1	10.9	0.0	60.0	550	C92
Haematology other	3	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.0	7.0	0.0	0.0	0.0	23.0	0.0	1610	C96

									Δ	sian M	lales												
Site	All Ages	Known Age	Unknown Age	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	LR74	ICD10
All sites	26	25	1	0.0	0.0	0.0	0.0	0.0	35.8	80.0	0.0	32.4	0.0	0.0	134.3	352.6	991.7	995.6	658.5	0.0	0.0	8	
All sites but C44	25	24	1	0.0	0.0	0.0	0.0	0.0	35.8	80.0	0.0	32.4	0.0	0.0	134.3	352.6	867.8	995.6	658.5	0.0	0.0	9	
Mouth	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	124.0	0.0	0.0	0.0	0.0	162	C06
Oesophagus	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	199.1	0.0	0.0	0.0	101	C15
Stomach	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	124.0	0.0	0.0	0.0	0.0	162	C16
Colorectal	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	67.1	0.0	0.0	0.0	0.0	0.0	0.0	298	C18
Liver & Bile duct	1	0	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	124.0	0.0	0.0	0.0	0.0	162	C22
Lung	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	26.7	0.0	0.0	0.0	0.0	0.0	0.0	124.0	0.0	0.0	0.0	0.0	133	C34
Skin other	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	124.0	0.0	0.0	0.0	0.0	162	C44
Kaposi's Sarcoma	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	26.7	0.0	0.0	0.0	0.0	0.0	0.0	124.0	0.0	0.0	0.0	0.0	133	C46
Prostate	8	8	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32.4	0.0	0.0	67.1	264.5	124.0	199.1	329.2	0.0	0.0	30	C61
Other specified	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	329.2	0.0	0.0		C63
Brain, CNS	1	1	0	0.0	0.0	0.0	0.0	0.0	35.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	559	C71
Primary site unknown	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	88.2	0.0	0.0	0.0	0.0	0.0	227	C80
NHL	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	199.1	0.0	0.0	0.0	101	C84
Leukaemia	3	3	0	0.0	0.0	0.0	0.0	0.0	0.0	26.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	398.2	0.0	0.0	0.0	48	C92
Haematology other	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	124.0	0.0	0.0	0.0	0.0	162	C96

											Black	Males											
Site	All Ages	Known Age	Unknown Age	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	LR74	ICD10
All sites but C44	691	685	6	10.3	9.8	7.2	5.3	3.8	11.2	19.9	31.4	38.0	61.0	98.7	160.8	282.5	264.7	465.8	576.2	637.8	730.2	14	
All sites	729	723	6	10.3	9.8	7.2	6.4	3.8	11.9	20.6	32.1	39.6	63.2	113.2	167.0	291.4	297.4	478.6	593.1	673.2	778.9	13	<u> </u>
Lip	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	9700	C00
Tongue	14	13	1	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.6	1.1	4.4	0.0	3.0	14.5	0.0	0.0	0.0	48.7	770	C02
Gum	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.0	0.0	0.0	3135	C03
Mouth	11	11	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	3.2	2.9	0.0	11.9	3.6	0.0	0.0	0.0	0.0	892	C06
Salivary gland	6	6	0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	4.1	0.0	0.0	6.4	0.0	0.0	48.7	1658	C07
Naso-Oropharynx	13	13	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	7.3	0.0	11.9	0.0	12.8	0.0	35.4	0.0	607	C11
Oesophagus	31	31	0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	0.8	5.4	8.7	12.4	5.9	21.8	19.1	0.0	0.0	0.0	265	C15
Stomach	17	17	0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	2.4	2.1	2.9	2.1	5.9	3.6	25.5	0.0	0.0	0.0	435	C16
Small intestine	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13779	C17
Colorectal	38	38	0	0.0	0.0	0.0	0.0	0.0	1.2	2.2	2.0	0.8	2.1	4.4	14.4	8.9	14.5	31.9	16.9	70.9	97.4	243	C18
Anus	9	9	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	1.6	2.1	0.0	0.0	0.0	3.6	0.0	0.0	35.4	0.0	2131	C21
Liver & Bile duct	13	13	0	0.0	0.0	0.0	0.0	0.0	1.9	0.7	0.0	1.6	1.1	0.0	2.1	5.9	10.9	0.0	0.0	0.0	0.0	827	C22
Pancreas	9	9	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	2.1	0.0	4.1	3.0	0.0	0.0	0.0	0.0	0.0	1604	C25
Larynx	12	12	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	8.2	8.9	3.6	6.4	16.9	0.0	0.0	665	C32
Lung	29	28	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	10.2	14.4	5.9	14.5	38.3	16.9	35.4	0.0	238	C34
Bone	5	5	0	0.0	0.0	1.0	0.0	0.8	0.0	0.0	0.7	0.0	1.1	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	2799	C41
Melanoma	7	7	0	0.0	0.0	1.0	0.0	0.0	0.6	0.0	0.0	0.8	0.0	0.0	4.1	3.0	0.0	6.4	0.0	0.0	0.0	1255	C43
Skin other	12	12	0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.7	0.0	1.1	4.4	4.1	3.0	7.3	6.4	0.0	0.0	0.0	729	C44
SCC of skin	18	18	0	0.0	0.0	0.0	1.1	0.0	0.0	0.7	0.0	1.6	0.0	8.7	2.1	3.0	14.5	6.4	16.9	0.0	0.0	526	C44
BCC	8	8	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.5	0.0	3.0	10.9	0.0	0.0	35.4	48.7	1222	C44
Mesothelioma	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	3.6	0.0	0.0	0.0	0.0	3516	C45

Kaposi's Sarcoma	53	52	1	0.0	0.0	0.0	0.0	0.8	0.6	8.1	8.0	7.3	7.5	5.8	2.1	8.9	3.6	0.0	50.8	0.0	0.0	380	C46
Connective tissue	7	7	0	1.6	0.0	0.0	0.0	0.0	0.6	0.7	0.0	0.0	0.0	2.9	0.0	0.0	3.6	0.0	0.0	0.0	0.0	2111	C49
Breast	5	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	2.1	0.0	2.1	0.0	3.6	0.0	0.0	0.0	0.0	2354	C50
Penis	7	7	0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	0.8	2.1	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2757	C60
Prostate	235	233	2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	10.7	18.9	63.9	157.6	130.5	274.4	406.7	460.6	535.5	31	C61
Testis	3	3	0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	3836	C62
Other specified	12	12	0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.3	1.6	0.0	1.5	4.1	3.0	7.3	6.4	0.0	0.0	0.0	774	C63
Kidney	7	7	0	0.8	1.8	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	2.1	3.0	0.0	0.0	0.0	0.0	0.0	2167	C64
Bladder	5	5	0	0.0	0.0	1.0	0.0	0.8	0.0	0.0	0.7	0.0	0.0	0.0	0.0	3.0	0.0	0.0	16.9	0.0	0.0	3688	C67
Eye	9	9	0	3.2	0.0	0.0	0.0	0.0	0.6	0.0	1.3	0.0	0.0	1.5	0.0	3.0	0.0	0.0	0.0	0.0	0.0	2092	C69
Brain, CNS	5	5	0	0.0	0.9	1.0	0.0	0.0	0.0	0.0	0.7	0.0	1.1	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	3014	C71
Thyroid	3	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7120	C73
Endocrine	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	27186	C74
Ill defined	9	9	0	0.0	0.0	0.0	1.1	0.8	0.0	0.0	0.7	0.0	0.0	4.4	0.0	3.0	3.6	0.0	16.9	0.0	0.0	1489	C76
Primary site																							
unknown	27	27	0	0.0	0.9	0.0	0.0	0.8	1.2	0.0	0.7	1.6	4.3	8.7	6.2	8.9	7.3	6.4	16.9	0.0	0.0	427	C80
Hodgkin																							
lymphoma	16	16	0	0.0	1.8	0.0	4.2	0.0	0.6	1.5	1.3	1.6	1.1	0.0	2.1	0.0	0.0	6.4	0.0	0.0	0.0	972	C81
Burkitt lymphoma	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24734	C83
NHL	36	35	1	0.0	0.0	2.1	0.0	0.0	3.1	1.5	4.0	6.5	5.4	4.4	4.1	3.0	3.6	0.0	16.9	0.0	0.0	533	C84
Myeloma	8	8	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	2.1	3.0	0.0	19.1	0.0	0.0	0.0	731	C90
Leukaemia	17	17	0	1.6	3.6	1.0	0.0	0.0	0.6	0.7	1.3	1.6	0.0	1.5	2.1	5.9	0.0	0.0	0.0	0.0	0.0	1002	C92
Haematology																							1
other	6	6	0	0.8	0.0	0.0	0.0	0.0	0.0	0.7	1.3	0.0	0.0	1.5	0.0	3.0	0.0	0.0	0.0	0.0	0.0	2744	C96

										Colou	ired M	ales											
Site	All Ages	Known Age	Unknown Age	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	LR74	ICD10
All sites but C44	24	23	1	0.0	0.0	31.3	0.0	0.0	28.6	0.0	20.4	53.4	0.0	140.0	191.9	706.1	175.1	195.2	658.3	0.0	5241.8	13.00	
All sites	25	24	1	0.0	0.0	31.3	0.0	0.0	28.6	0.0	20.4	53.4	0.0	186.7	191.9	706.1	175.1	195.2	658.3	0.0	5241.8	13.00	
Mouth	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	750.00	C06
Colorectal	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	235.4	0.0	0.0	0.0	0.0	0.0	85.00	C18
Pancreas	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	117.7	0.0	0.0	0.0	0.0	0.0	170.00	C25
Larynx	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	20.4	0.0	0.0	0.0	0.0	0.0	87.6	0.0	0.0	0.0	0.0	186.00	C32
Lung	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	87.6	0.0	658.3	0.0	0.0	229.00	C34
Skin other	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	46.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	429.00	C44
Breast	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	46.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	429.00	C50
Prostate	6	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	46.7	96.0	117.7	0.0	195.2	0.0	0.0	2620.9	44.00	C61
Еуе	1	1	0	0.0	0.0	31.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	640.00	C69
Brain, CNS	1	0	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2620.9		C71
Ill defined	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	48.0	0.0	0.0	0.0	0.0	0.0	0.0	417.00	C76
Primary site unknown	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	117.7	0.0	0.0	0.0	0.0	0.0	170.00	C80
Non Hodgkin lymphoma	3	3	0	0.0	0.0	0.0	0.0	0.0	28.6	0.0	0.0	26.7	0.0	0.0	48.0	0.0	0.0	0.0	0.0	0.0	0.0	194.00	C84
Leukaemia	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	46.7	0.0	117.7	0.0	0.0	0.0	0.0	0.0	122.00	C92

											Whit	e Male	25										
Site	All Ages	Known Age	Unknown Age	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	LR74	ICD10
All sites	634	585	49	26.5	0.0	8.9	7.3	7.1	36.8	55.5	60.3	43.6	147.5	211.0	358.2	722.0	695.4	1011.7	1101.6	2005.3	1586.1	6	
All sites but																							
C44	567	519	48	26.5	0.0	8.9	7.3	7.1	36.8	55.5	54.8	32.7	117.0	180.9	315.0	639.3	636.5	931.9	1029.2	1621.3	1448.2	7	
Lip	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.9	0.0	0.0	0.0	2254	C00
Tongue	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.5	0.0	0.0	0.0	0.0	0.0	2660	C02
Mouth	4	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	6.2	0.0	0.0	8.9	14.5	0.0	0.0	949	C06
Salivary gland	3	2	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	11.8	0.0	0.0	0.0	0.0	1123	C07
Naso-	5	4	1	0.0	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.0	6.0	0.0	0.0	5.9	0.0	14.5	0.0	69.0	1061	C11
Oropharynx			1																				
Oesophagus	16	11	5	8.8	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.0	15.3	6.0	6.2	7.5	5.9	17.7	58.0	42.7	0.0	275	C15
Stomach	14	10	4	0.0	0.0	0.0	0.0	0.0	7.4	0.0	0.0	0.0	0.0	6.0	0.0	30.1	23.6	26.6	0.0	42.7	0.0	214	C16
Colorectal	62	53	9	0.0	0.0	0.0	0.0	0.0	0.0	6.9	11.0	10.9	25.4	30.1	43.2	37.6	94.3	35.5	87.0	298.7	137.9	68	C18
Anus	6	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.0	11.8	0.0	0.0	0.0	137.9	746	C21
Liver & Bile																							
duct	4	3	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.4	7.5	5.9	0.0	0.0	0.0	0.0	777	C22
Pancreas	15	10	5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.0	12.4	15.0	35.4	35.5	0.0	0.0	0.0	193	C25
Larynx	4	3	1	0.0	0.0	8.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.0	5.9	0.0	0.0	0.0	0.0	671	C32
Lung	37	33	4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	5.1	12.1	18.5	52.6	29.5	44.4	116.0	170.7	69.0	120	C34
Bone	3	3	0	0.0	0.0	0.0	7.3	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.0	0.0	5.9	0.0	0.0	0.0	0.0	1074	C41
Melanoma	28	27	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	5.4	5.1	24.1	0.0	22.6	29.5	44.4	72.5	85.3	69.0	147	C43
SCC of skin	10	10	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	6.0	6.2	0.0	11.8	0.0	14.5	128.0	69.0	688	C44
BCC	46	46	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	10.9	25.4	24.1	37.1	60.2	35.4	62.1	29.0	170.7	69.0	77	C44
Skin other	11	10	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.6	11.8	17.7	29.0	85.3	0.0	384	C44
Mesothelioma	4	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.2	0.0	0.0	8.9	29.0	0.0	0.0	1329	C45

Kaposi's																							
Sarcoma	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.5	0.0	0.0		C46
Connective																							
tissue	4	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.0	0.0	8.9	0.0	42.7	0.0	837	C49
Breast	3	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.0	17.7	0.0	0.0	0.0	842	C50
Penis	2	1	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	0.0	0.0	0.0	69.0	3394	C60
Prostate	222	215	7	8.8	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	35.6	30.1	111.2	278.3	259.3	514.7	434.9	512.0	620.7	17	C61
Testis	4	4	0	0.0	0.0	0.0	0.0	0.0	7.4	6.9	11.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	792	C62
Other																							
specified	7	7	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.1	6.2	7.5	5.9	8.9	14.5	0.0	0.0	494	C63
Kidney	11	10	1	0.0	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	5.1	6.0	12.4	7.5	11.8	17.7	0.0	42.7	0.0	297	C64
Bladder	14	13	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.0	15.0	23.6	8.9	29.0	85.3	137.9	378	C67
Eye	1	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3933	C69
Brain, CNS	14	12	2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.1	12.4	7.5	11.8	35.5	14.5	0.0	69.0	235	C71
Endocrine	2	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.0	0.0	0.0	0.0	0.0	0.0	1330	C74
Ill defined	3	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.2	0.0	11.8	0.0	0.0	0.0	0.0	1114	C76
Primary site																							
unknown	22	21	1	0.0	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	10.2	6.0	0.0	22.6	17.7	53.2	43.5	128.0	0.0	172	C80
Hodgkin																							
lymphoma	7	7	0	0.0	0.0	0.0	0.0	0.0	14.7	6.9	0.0	0.0	0.0	0.0	6.2	22.6	0.0	0.0	0.0	0.0	0.0	397	C81
NHL	19	19	0	0.0	0.0	0.0	0.0	7.1	0.0	6.9	11.0	5.4	5.1	6.0	24.7	15.0	0.0	17.7	29.0	85.3	0.0	202	C84
Myeloma	10	9	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.0	12.4	0.0	23.6	8.9	29.0	0.0	0.0	401	C90
Leukaemia	14	12	2	8.8	0.0	0.0	0.0	0.0	7.4	0.0	0.0	0.0	0.0	0.0	18.5	22.6	0.0	8.9	29.0	85.3	69.0	303	C92